Document:

EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

Dated as of March 13, 2018 

by and between 

ATHERSYS, INC. 
 and

 HEALIOS K.K. 
  

 

 TABLE OF CONTENTS 

 

							
		  		  	 	 Page
	 
		
	 ARTICLE I       PURCHASE AND SALE
	  	 	1	 
			
	 1.1
	  	 Subscription of the Shares and the Warrant
	  	 	1	 
			
	 1.2
	  	 Purchase Price of the Shares and the Warrant
	  	 	1	 
			
	 1.3
	  	 Exemption from Registration
	  	 	1	 
		
	 ARTICLE II      THE CLOSING
	  	 	2	 
			
	 2.1
	  	 Closing and Closing Date
	  	 	2	 
			
	 2.2
	  	 Closing and Post-Closing Deliveries
	  	 	2	 
		
	 ARTICLE III      REPRESENTATIONS AND WARRANTIES OF
THE COMPANY
	  	 	3	 
			
	 3.1
	  	 Organization; Good Standing; Qualification and Power
	  	 	3	 
			
	 3.2
	  	 Subsidiaries
	  	 	3	 
			
	 3.3
	  	 Authorization
	  	 	3	 
			
	 3.4
	  	 Noncontravention; No Consent or Approval Required
	  	 	4	 
			
	 3.5
	  	 Compliance with Laws; Organizational Documents
	  	 	4	 
			
	 3.6
	  	 Capitalization of the Company
	  	 	4	 
			
	 3.7
	  	 Material Agreements
	  	 	5	 
			
	 3.8
	  	 Brokers
	  	 	5	 
			
	 3.9
	  	 Financial Statements
	  	 	5	 
			
	 3.10
	  	 Changes
	  	 	6	 
			
	 3.11
	  	 Absence of Undisclosed Liabilities
	  	 	6	 
			
	 3.12
	  	 Title to Assets, Properties and Rights
	  	 	6	 
			
	 3.13
	  	 Taxes
	  	 	7	 
			
	 3.14
	  	 Litigation and Other Proceedings
	  	 	7	 
		
	 ARTICLE IV      REPRESENTATIONS AND WARRANTIES OF
BUYER
	  	 	7	 
			
	 4.1
	  	 Experience; Accredited Investor Status
	  	 	7	 
			
	 4.2
	  	 Company Information
	  	 	8	 
			
	 4.3
	  	 Investment
	  	 	8	 
			
	 4.4
	  	 Transfer Restrictions
	  	 	8	 
			
	 4.5
	  	 Brokers or Finders
	  	 	8	 
			
	 4.6
	  	 Organization; Qualification and Power
	  	 	8	 
			
	 4.7
	  	 Authorization
	  	 	9	 

  

					
		 	-i-	  	CONFIDENTIAL

 TABLE OF CONTENTS 

(continued) 
  

							
		  		  	 	 Page
	 
			
	 4.8
	  	 No Consent or Approval Required
	  	 	9	 
			
	 4.9
	  	 No Prior Short Selling
	  	 	9	 
			
	 4.10
	  	 Beneficial Ownership of Common Stock
	  	 	9	 
		
	 ARTICLE V       MISCELLANEOUS
	  	 	9	 
			
	 5.1
	  	 Expenses
	  	 	9	 
			
	 5.2
	  	 No Third Party Beneficiaries
	  	 	10	 
			
	 5.3
	  	 Complete Agreement
	  	 	10	 
			
	 5.4
	  	 Successors and Assigns
	  	 	10	 
			
	 5.5
	  	 Counterparts
	  	 	10	 
			
	 5.6
	  	 Press Releases and Public Announcements
	  	 	10	 
			
	 5.7
	  	 Notices
	  	 	11	 
			
	 5.8
	  	 Confidentiality
	  	 	12	 
			
	 5.9
	  	 Governing Law
	  	 	13	 
			
	 5.10
	  	 Jurisdiction; Venue
	  	 	13	 
			
	 5.11
	  	 Jury Trial
	  	 	13	 
			
	 5.12
	  	 Amendments and Waivers
	  	 	13	 
			
	 5.13
	  	 Termination
	  	 	13	 
			
	 5.14
	  	 Headings
	  	 	13	 
			
	 5.15
	  	 Certain Definitions
	  	 	14	 
			
	 5.16
	  	 Incorporation of Schedules and Exhibits
	  	 	16	 
			
	 5.17
	  	 Rules of Construction
	  	 	17	 
			
	 5.18
	  	 Severability
	  	 	18	 

 SCHEDULES AND EXHIBITS 
  

			
	 3.6(a)(i)
	  	Capitalization of the Company - Authorized Capital Stock (pre-Closing)
	 3.6(a)(ii)
	  	Capitalization of the Company - Issued and Outstanding Capital Stock (pre-Closing)
	 3.6(b)
	  	Outstanding Warrants, Options, Rights, Agreements, etc.
	 3.10
	  	Changes
		
	 Exhibit A
	  	Form of Warrant

  

					
		 	-ii-	  	CONFIDENTIAL

 SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”), is made as of March 13, 2018, by and
between Athersys, Inc. (the “Company”) and HEALIOS K.K. (“Buyer”). The Company and Buyer are herein referred to as the “Parties.” 

WHEREAS, the Company has authorized the sale of the Shares and the Warrant to Buyer; and 

WHEREAS, Buyer wishes to purchase, and the Company wishes to issue and sell, the Shares and the Warrant on the terms and
subject to the conditions set forth herein. 
 NOW THEREFORE, in consideration of the premises and the mutual covenants
contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Buyer hereby agree as follows: 

ARTICLE I 
 PURCHASE
AND SALE 
  

	1.1	 Subscription of the Shares and the Warrant. 

Buyer hereby confirms its subscription for and offer to purchase the Shares and the Warrant from the Company on and subject to
the terms and conditions of this Agreement. The Company hereby accepts the subscription by the Buyer. 
  

	1.2	 Purchase Price of the Shares and the Warrant. 

The amount payable by Buyer, in the aggregate, to the Company for the purchase of the Shares and the Warrant pursuant to this
Agreement will be the Subscription Amount. 
  

	1.3	 Exemption from Registration. 

(a)    The Shares, the Warrant and the Warrant Shares (i) have not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), or any applicable state or other securities laws, (ii) will be issued under an exemption or exemptions from registration under the Securities Act and any
applicable state and other securities laws, and (iii) will be restricted securities (as that term is defined in Rule 144(a)(3) promulgated under the Securities Act) and may not be resold unless such Shares, Warrant and Warrant Shares are
registered under the Securities Act and any applicable state and other securities laws or an exemption from registration is available. 

(b)    Accordingly, the Shares, the Warrant and the Warrant Shares shall, upon issuance, bear legends in
substantially the following form (in addition to any other legends required to be placed thereon under applicable securities laws), and the Company shall give instructions to the Transfer Agent in order to implement the restrictions on transfer set
forth and described herein and in the Investor Rights Agreement: 

  
 CONFIDENTIAL 

 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY OTHER APPLICABLE
SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE SECURITIES LAWS. 

ARTICLE II 
 THE
CLOSING 
  

	2.1	 Closing and Closing Date. 

The closing of the sale of the Shares and the Warrant (the “Closing”) shall take place at the offices
of Jones Day, 901 Lakeside Avenue, Cleveland, Ohio, on the earliest practicable date, but no later than the third (3rd) Business Day following the date hereof (the “Closing
Date”). At the Closing, on the terms and subject to the conditions contained herein, the Company shall issue, sell and deliver to Buyer, and Buyer shall purchase and acquire from the Company, the Shares, free and clear of any Liens and
with no restrictions on the transfer thereof (in each case other than pursuant to this Agreement and pursuant to the federal securities laws). 
  

	2.2	 Closing and Post-Closing Deliveries. 

(a)    At the Closing, the Company shall: 

(i)    irrevocably instruct the Transfer Agent to record the issuance of the Shares to Buyer in
book-entry form pursuant to the Transfer Agent’s regular procedures; 
 (ii)    deliver to Buyer
the Warrant registered in the name of Buyer; 
 (iii)    deliver to Buyer a certificate of good
standing in respect of the Company issued by the Secretary of State of the State of Delaware dated as of a date within five (5) Business Days of the Closing Date; and 

(iv)    deliver to Buyer a copy of the investor rights agreement, dated as of the Closing Date, (the
“Investor Rights Agreement”), between the Company and Buyer, addressing the respective rights and obligations of Buyer as an investor in the Company, duly executed by the Company. 

(b)    At the Closing, Buyer shall deliver to the Company: 

(i)    by bank wire transfer of immediately available funds of U.S. dollars to an account designated in
writing by the Company, an amount in cash equal to the Subscription Amount; and 

  
 2 

 (ii)    a copy of the Investor Rights Agreement, duly
executed by Buyer. 
 (c)    As promptly as practicable following the Closing, the Company shall deliver
to Buyer evidence from the Transfer Agent of the issuance of the Shares. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby represents and warrants to Buyer as of the date hereof as follows and acknowledges and confirms that Buyer
is relying upon such representations and warranties in entering into this Agreement and consummating the transactions contemplated herein: 
  

	3.1	 Organization; Good Standing; Qualification and Power. 

The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware,
has all requisite power and authority to own, lease and operate its assets and to carry on its business as presently being conducted, and is qualified to do business and is in good standing in every jurisdiction in which the failure so to qualify or
be in good standing could reasonably be expected to have a Material Adverse Effect. 
  

	3.2	 Subsidiaries. 

Each of the Subsidiaries is duly organized, validly existing and in good standing under the laws of its jurisdiction of
organization and is in good standing under such laws. Each of the Subsidiaries is wholly owned by the Company. None of the Subsidiaries owns or leases property or engages in any activity in any jurisdiction that might require its qualification to do
business as a foreign corporation in such jurisdiction and in which the failure to qualify as such would have a Material Adverse Effect. Other than the Company’s ownership of the Subsidiaries, the Company does not currently own or control,
directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. 
  

	3.3	 Authorization. 

(a)    The Company has all requisite power and authority to execute and deliver each of the Transaction
Documents and any and all instruments necessary or appropriate in order to effectuate fully the terms hereof and thereof and all related transactions and to perform its obligations hereunder and thereunder. Each of the Transaction Documents has been
duly authorized by all necessary corporate action of, and executed and delivered by, the Company. 

  
 3 

 (b)    The issuance, sale and delivery of the Shares, the
Warrant and the Warrant Shares have been duly authorized by all necessary corporate action of the Company. The Shares, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration provided for herein, will
be validly issued, fully paid and non-assessable. The Warrant Shares, when issued and delivered by the Company pursuant to the Warrant against payment of the consideration provided for therein, will be validly
issued, fully paid and non-assessable. 
  

	3.4	 Noncontravention; No Consent or Approval Required. 

The execution, delivery and performance by the Company of the Transaction Documents and the consummation of the transactions
contemplated hereby and thereby have not and will not (a) violate any provision of the Organizational Documents of the Company, (b) violate any law to which the Company or any of its assets is subject, (c) result in a breach of,
constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel any Contract to which the Company or any of the Subsidiaries is a party or by which any of the assets of the Company
or any of the Subsidiaries is bound, or (d) result in the imposition of any Lien upon any of the assets of the Company or the Subsidiaries or the obligation by the Company or any Subsidiary to pay any penalty or premium which, with respect to
each of the foregoing clauses, could reasonably be expected to have a Material Adverse Effect. No consent, approval or authorization of, declaration or notice to, or filing with, any Person is required by the Company for the valid authorization,
execution and delivery by the Company of the Transaction Documents or for the consummation of the transactions contemplated hereby and thereby, other than (x) those consents, approvals, authorizations, declarations or filings that have been
obtained or made, as the case may be, and (y) filings pursuant to federal or state securities and other applicable laws, including the filing of a Form D with the Securities and Exchange Commission (the “SEC”), that
(other than those which are permitted to be made after the Closing and which will be duly made in accordance with time periods under applicable laws), have been made by the Company in connection with the sale of the Shares and the Warrant. 

 

	3.5	 Compliance with Laws; Organizational Documents. 

The Company (a) has complied in all material respects with, and is in material compliance with, all laws applicable to it
and its business, and (b) has all Permits used or necessary in the conduct of its business as presently conducted, other than such Permits that, if not obtained, could not reasonably be expected to have a Material Adverse Effect. Such Permits
are in full force and effect, the Company has not received notice of any material violations with respect to any thereof, and no material Proceeding is pending or, to the Company’s knowledge, threatened to revoke or limit any thereof. 

 

	3.6	 Capitalization of the Company. 

(a)    As of the date hereof, (i) the authorized capital stock of the Company consisted of the
classes and amounts set forth on Schedule 3.6(a)(i), and (ii) the issued and outstanding capital stock of the Company (separated by class and series) was as set forth on Schedule 3.6(a)(ii). 

  
 4 

 (b)    Except as contemplated by this Agreement, including
pursuant to the Warrant, or as set forth on Schedule 3.6(b) or as otherwise have been waived, as of the date hereof, there are no (i) outstanding warrants, options, rights, agreements, convertible securities or other commitments
or instruments pursuant to which the Company is or may become obligated to issue or sell any shares of its capital stock or other securities or (ii) preemptive or similar rights to purchase or otherwise acquire shares of the capital stock or
other securities of the Company pursuant to any provision of law, the Company’s Organizational Documents or any Contract to which the Company, or to the Company’s knowledge, any stockholder thereof, is a party. 

 

	3.7	 Material Agreements. 

To the Company’s knowledge, (a) there is no material breach or default by any party under any Contract to which the
Company or any Subsidiary is a party that is material to the Company’s or any Subsidiary’s business, operations, assets, financial condition or operating results (each, a “Material Agreement”) and (b) each
Material Agreement is in full force and effect, constitutes the valid and binding obligation of the respective parties thereto (assuming due execution by the parties other than the Company or its subsidiaries, as applicable), and is enforceable in
accordance with its terms, except as enforceability thereof may be limited by applicable bankruptcy, reorganization, insolvency or other laws affecting creditors’ rights generally or by general principles of equity. The Company has publicly
filed or provided to Buyer complete and accurate copies of each Material Agreement. 
  

	3.8	 Brokers. 

On behalf of the Company, there is no agent, broker, investment banker, consultant, Person or firm that has acted on behalf,
or under the authority of, the Company or, to the Company’s knowledge, any of its stockholders, or will be entitled to any fee or commission directly or indirectly from the Company or, to the Company’s knowledge, any of its stockholders,
in connection with any of the transactions contemplated by the Transaction Documents. 
  

	3.9	 Financial Statements. 

The Company has filed with the SEC its audited balance sheet as of December 31, 2016 (the “Statement
Date”), and the audited statements of income and cash flows for the year ending on the Statement Date (together, the “Audited Financial Statements”) and the unaudited balance sheet and statements of income and
cash flows for the nine-month period ended September 30, 2017 (the “Interim Financial Statements”). The Audited Financial Statements, together with the notes thereto, have been prepared in accordance with GAAP,
consistently applied throughout the periods indicated and present fairly, in all material respects, the financial condition and position and results of operation of the Company as of the Statement Date and for the period indicated. The Interim
Financial Statements present fairly, in all material respects, the financial condition and position and results of operations of the Company as of the date and for the period indicated, and have been prepared in accordance with GAAP, except for the
absence of footnote disclosure and customary year-end adjustments. 

  
 5 

	3.10	 Changes. 

Except as set forth in the SEC Reports or as set forth on Schedule 3.10, since September 30, 2017, there
has not been: 
 (a)    Any change in or effect on the assets, Liabilities, financial condition or
operations of the Company from that reflected in the Interim Financial Statements, other than changes in the ordinary course of business, none of which individually or in the aggregate has had or could reasonably be expected to have a Material
Adverse Effect; 
 (b)    Any waiver by the Company of a material right of the Company or a material
debt owed to the Company; 
 (c)    Any direct or indirect loans made by the Company to any stockholder,
employee, officer or director of the Company, other than advances made in the ordinary course of business; 

(d)    Any debt, obligation or liability incurred, assumed or guaranteed by the Company, except for
advances from customers and those for immaterial amounts and for current Liabilities incurred in the ordinary course of business; 

(e)    Any change in any Material Agreement which has had or could reasonably be expected to have a
Material Adverse Effect; or 
 (f)    Any other event or condition of any character that, either
individually or cumulatively, has had or could reasonably be expected to have a Material Adverse Effect. 
  

	3.11	 Absence of Undisclosed Liabilities. 

Neither the Company nor any of the Subsidiaries has any material Liabilities, except (a) to the extent reflected or
reserved against on the balance sheet included in the Interim Financial Statements or disclosed in the Audited Financial Statements and (b) Liabilities arising in the ordinary course of business consistent with past practice since
September 30, 2017. There are no material loss contingencies (as such term is used in Statement of Financial Accounting Standards No. 5, or any successor thereto, issued by the Financial Accounting Standards Board) of or affecting the
Company or any of the Subsidiaries which are required to be disclosed or for which adequate provision was required to be made on the balance sheet included in the Interim Financial Statements or in the Audited Financial Statements which have not
been disclosed or for which adequate provision has not been made on the balance sheet included in the Interim Financial Statements or in the Audited Financial Statements or in the notes thereto. 

 

	3.12	 Title to Assets, Properties and Rights. 

The Company and the Subsidiaries have good and marketable title to all real property owned by them and have good title to all
personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described in the SEC Reports or such as do not materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company and the Subsidiaries; and any real property and buildings held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries. 

  
 6 

	3.13	 Taxes. 

Except as would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect: (A) the
Company and each of the Subsidiaries have filed all United States federal, state, local and foreign income Tax returns required by law to be filed through the date hereof and the returns and reports are true and correct in all material respects. All
Taxes shown by such returns or otherwise assessed, which are due and payable, have been paid other than Taxes that the Company or any of the Subsidiaries are contesting in good faith and as to which adequate reserves have been established in
accordance with GAAP; and (B) there is no deficiency that has been asserted in writing against the Company or any of the Subsidiaries or any of their respective properties or assets other than Tax deficiencies that the Company or any of the
Subsidiaries are contesting in good faith and as to which adequate reserves have been established in accordance with GAAP. 
  

	3.14	 Litigation and Other Proceedings. 

There are no Proceedings pending or, to the Company’s knowledge, threatened against the Company, any of the Subsidiaries
or their properties, whether at law or in equity, whether civil or criminal in nature, that are or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF BUYER 

Buyer represents and warrants to the Company as of the date hereof as follows and acknowledges and confirms that Company is
relying upon such representations and warranties in entering into this Agreement and consummating the transactions contemplated herein: 
  

	4.1	 Experience; Accredited Investor Status. 

Buyer (a) is an accredited investor as that term is defined in Rule 501 of Regulation D promulgated under the
Securities Act and, by virtue of its experience in evaluating and investing in private placement transactions of securities in companies similar to the Company, (b) is capable of evaluating the merits and risks of its investment in the Company
and has the capacity to protect its own interests, (c) has the financial ability to bear the economic risk of its investment in the Company and (d) is not purchasing the Shares, the Warrant or any Warrant Shares as a result of any
advertisement, article, notice or other communication regarding the Shares, the Warrant or any Warrant Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or other general
solicitation or general advertisement. 

  
 7 

	4.2	 Company Information. 

Buyer has been provided access to all information regarding the business and financial condition of the Company, its expected
plans for future business activities, material contracts, intellectual property, and the merits and risks of its purchase of the Shares, the Warrant and any Warrant Shares, which Buyer has reasonably requested or otherwise needs to evaluate an
investment in the Shares, the Warrant and any Warrant Shares. Buyer has had an opportunity to discuss the Company’s business, management and financial affairs with directors, officers and management of the Company and has had the opportunity to
review the Company’s operations and facilities. Buyer has also had the opportunity to ask questions of and receive answers from, the Company and its management regarding the terms and conditions of this investment and all such questions have
been answered to Buyer’s satisfaction. 
  

	4.3	 Investment. 

Buyer is acquiring the Shares, the Warrant and any Warrant Shares for investment for its own account, not as a nominee or
agent, and not with the view to, or for resale in connection with, any distribution of any part thereof. Buyer understands that the Shares, the Warrant and the Warrant Shares have not been registered under the Securities Act or applicable state and
other securities laws and are being issued by reason of a specific exemption from the registration provisions of the Securities Act and applicable state and other securities laws, the availability of which depends upon, among other things, the bona
fide nature of the investment intent and the accuracy of Buyer’s representations as expressed herein. 
  

	4.4	 Transfer Restrictions. 

Buyer acknowledges and understands that (a) transfers of the Shares, the Warrant and any Warrant Shares are subject to
transfer restrictions contained in this Agreement, the Warrant, the Investor Rights Agreement and under the federal securities laws and (b) Buyer must bear the economic risk of this investment for an indefinite period of time because the
Shares, the Warrant and any Warrant Shares must be held indefinitely unless subsequently registered under the Securities Act and applicable state and other securities laws or unless an exemption from such registration is available. 

 

	4.5	 Brokers or Finders. 

Buyer has not retained any agent, broker, investment banker, consultant, Person or firm that has acted on behalf of, or under
the authority of, Buyer or, to Buyer’s knowledge, any of its stockholders, or that will be entitled to any fee or commission directly or indirectly from Buyer or, to Buyer’s knowledge, any of its stockholders, in connection with any of the
transactions contemplated by the Transaction Documents. 
  

	4.6	 Organization; Qualification and Power. 

Buyer is company duly organized and validly existing under the laws of Japan, has all requisite power and authority to own,
lease and operate its assets and to carry on its business as presently being conducted, and is qualified to do business and in good standing in every jurisdiction in which the failure so to qualify or be in good standing could reasonably be expected
to have a Material Adverse Effect on Buyer. 

  
 8 

	4.7	 Authorization. 

Buyer has all requisite power and authority to execute and deliver each of the Transaction Documents and any and all
instruments necessary or appropriate in order to effectuate fully the terms hereof and thereof and all related transactions, and to perform its obligations hereunder and thereunder. Buyer’s entry into each of the Transaction Documents and its
performance of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate or limited liability company action, as applicable, of, and executed and delivered by, Buyer. Subject to the Company’s
execution and delivery of this Agreement, this Agreement is a valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms, except as enforceability may be limited by applicable equitable principles or by bankruptcy,
insolvency, reorganization, moratorium, or similar laws affecting creditors’ rights generally, and by the exercise of judicial discretion in accordance with equitable principles. 

 

	4.8	 No Consent or Approval Required. 

No consent, approval or authorization of, or declaration to or filing with, any Person shall be required by Buyer for the
valid authorization, execution and delivery by such Buyer of this Agreement or for the consummation of the transactions contemplated hereby other than those consents, approvals, authorizations, declarations or filings which have been obtained or
made, as the case may be. 
  

	4.9	 No Prior Short Selling. 

Buyer has no present intention to and at no time prior to the date of this Agreement has any of Buyer, its agents,
representatives or affiliates engaged in or effected, in any matter whatsoever, directly or indirectly, any (i) “short sale” (as such term is defined in Section 242.200 of Regulation SHO of the Exchange Act) of the Common Stock or
(ii) hedging transaction, which establishes a net short position with respect to the Common Stock. 
  

	4.10	 Beneficial Ownership of Common Stock. 

As of the date hereof, Buyer is not a Beneficial Owner of (a) any Common Stock or (b) any securities or other
instruments representing the right to acquire Common Stock. Other than pursuant to the Investor Rights Agreement, Buyer does not have a formal or informal agreement, arrangement or understanding with any Person to acquire, dispose of or vote any
securities of the Company. 
 ARTICLE V 

MISCELLANEOUS 
  

	5.1	 Expenses. 

Each Party will pay its own expenses incurred in connection with the transactions contemplated by this Agreement, including,
without limitation, any broker fees or expenses of financial advisors, financial sponsors, legal counsel or other advisors. 

  
 9 

	5.2	 No Third Party Beneficiaries. 

Except as expressly provided herein, this Agreement shall not confer any rights or remedies upon any Person other than the
Parties hereto and their respective successors and permitted assigns, personal representatives, heirs and estates, as the case may be. 
  

	5.3	 Complete Agreement. 

This Agreement constitutes the entire agreement among the Parties hereto with respect to the transactions contemplated hereby
and supersede any prior understandings, agreements or representations by or among such Parties, written or oral, that may have related in any way to the purchase and sale of the Shares and the Warrant. 

 

	5.4	 Successors and Assigns. 

This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and
permitted assigns. None of the Parties hereto shall be permitted to assign its rights or obligations hereunder without the prior written consent of the other Party hereto. 
  

	5.5	 Counterparts. 

This Agreement may be executed in any number of counterparts; each such counterpart shall be deemed to be an original
instrument and all counterparts together shall constitute one instrument. This Agreement may also be executed and delivered by portable document format (pdf) and in two or more counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. 
  

	5.6	 Press Releases and Public Announcements. 

The Parties will agree upon the timing and content of any initial press release, or other public communications relating to
this Agreement and the transactions contemplated herein. 
 (a)    Except to the extent already
disclosed in any initial press release or other public communication, no public announcement concerning the existence or the terms of this Agreement or concerning the transactions described herein shall be made, either directly or indirectly, by any
of the Parties hereto without such Party first obtaining the approval of the other Parties and agreement upon the nature, text, and timing of such announcement, which approval and agreement shall not be unreasonably withheld; provided,
however, that nothing in this Section 5.6 shall be deemed to prohibit any Party from making any disclosure which its counsel deems necessary or advisable in order to satisfy such Party’s
disclosure obligations imposed by law or by Tokyo Stock Exchange rule or regulation, including, but not limited to, obligations pursuant to the Exchange Act, and provided further that each Party acknowledges that this Agreement and the
Investor Rights Agreement will be filed with the SEC by the Company. 

  
 10 

 (b)    The Party desiring to make any such public
announcement shall provide the other Parties with a written copy of the proposed announcement in sufficient time prior to public release to allow such other Parties to comment upon such announcement, prior to public release. 

 

	5.7	 Notices. 

All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be deemed to have been
duly given if delivered personally, via electronic mail, by facsimile, sent by nationally recognized overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the appropriate Party at the address,
email address or facsimile number, as applicable, set forth below (or at such other address for such Party as shall be specified by like notice): 

If to the Company, to: 

Athersys, Inc. 

3201 Carnegie Avenue 

Cleveland, OH 44115 

Telephone: (216) 431-9900 

Facsimile: (216) 361-9495 

Email: lcampbell@athersys.com 

Attention: Senior Vice President of Finance 

with a copy (which will not constitute notice) to: 

Jones Day 

901 Lakeside Avenue 

Cleveland, Ohio 44114 

Telephone: (216)586-7103 

Facsimile: (216) 579-0212 

Email: mjsolecki@jonesday.com 

Attention: Michael J. Solecki 

If to Buyer, to: 

HEALIOS K.K. 

Attention: General Manager of Finance and Accounting Division 

World Trade Center Bldg. 15F 

2-4-1 Hamamatsucho, 

Minato-ku, Tokyo, 135-6115
Japan 
 Facsimile:
+81-3-3434-7231 

  
 11 

 with a copy (which will not constitute notice) to: 

Morrison & Foerster LLP 

Shin-Marunouchi Building, 29th Floor 

1-5-1 Marunouchi, Chiyoda-ku, Tokyo 
 100-6529,
Japan 
 Telephone:
+81-3-3214-6522 
 Facsimile:
+81-3-3214-6512 
 Email:
RLaxer@mofo.com 
 Attention: Randy S. Laxer 

and to: 

Morrison & Foerster LLP 

250 West 55th Street 

New York, NY 10019-9601, U.S.A. 

Telephone: +1 (212) 468-8000 

Facsimile: +1 (212) 468-7900 

Email: JBell@mofo.com 

Attention: Jeffrey Bell 

All such notices and other communications shall be deemed to have been given and received (i) in the case of personal
delivery, on the date of such delivery, (ii) in the case of delivery by email or facsimile, (A) when delivered prior to 5:00 p.m. (New York time) on a Business Day or (B) if delivered after 5:00 p.m. on a Business Day or on a day that
is not a Business Day, on the first Business Day following the date of delivery, (iii) in the case of delivery by nationally recognized overnight courier, on the second Business Day following the date when sent, and (iv) in the case of
mailing, on the fifth Business Day following such mailing. 
  

	5.8	 Confidentiality. 

Buyer shall, and shall cause its respective officers, directors, employees, agents, affiliates and its affiliate’s
officers, directors, employees and agents, if any, to, hold confidential and not use in any manner detrimental to the Company all information they may have or obtain pursuant to their rights under this Agreement concerning the Company and its
assets, business, operations, or prospects; provided, however, that the foregoing shall not apply to (a) information that is or becomes generally available to the public other than as a result of the improper disclosure by Buyer or any
of its affiliates or its or its affiliates’ employees, agents, accountants, legal counsel or other representatives, (b) information that is or becomes available to Buyer or any of its employees, agents, accountants, legal counsel, or other
representatives on a non-confidential basis prior to its disclosure by the Company or its employees, agents, accountants, legal counsel or other representatives, (c) information that is required to be
disclosed by Buyer or any of its affiliates or its or its affiliates’ employees, agents, accountants, legal counsel, or other representatives as a result of any applicable law, rule, or regulation of any Governmental Entity or stock exchange
and (d) any information that is reasonably required to be disclosed by Buyer in order to enforce its rights pursuant to this Agreement. 

  
 12 

	5.9	 Governing Law. 

This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving effect
to the principles of conflict of laws thereof. 
  

	5.10	 Jurisdiction; Venue. 

Each of the Parties hereto hereby submits and consents irrevocably to the exclusive jurisdiction of the courts of the State of
New York and the United States District Court for the Southern District of New York for the interpretation and enforcement of the provisions of this Agreement. Each of the Parties hereto also agrees that the jurisdiction over the person of such
Parties and the subject matter of such dispute shall be effected by the mailing of process or other papers in connection with any such action in the manner provided for in Section 5.7 or in such other
manner as may be lawful, and that service in such manner shall constitute valid and sufficient service of process. 
  

	5.11	 Jury Trial. 

EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF
ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 
  

	5.12	 Amendments and Waivers. 

This Agreement may be amended or modified and the terms and conditions hereof may be waived, only by a written instrument
signed by the Company and Buyer or, in the case of a waiver, the Party or Parties hereto waiving compliance. No delay on the part of any Party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall
any waiver on the part of any Party hereto of any right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege hereunder, preclude any other or other exercise thereof hereunder. The rights and remedies
herein provided are cumulative and are not exclusive of any rights or remedies which any Party hereto may otherwise have at law or in equity. 
  

	5.13	 Termination. 

The representations and warranties of the Company and Buyer contained in Articles III and IV
hereof and the agreements and covenants set forth in this Article V shall survive the termination of this Agreement. No termination of this Agreement shall affect the Company’s or Buyer’s rights or obligations under the
Investor Rights Agreement, which shall survive any such termination in accordance with its terms. 
  

	5.14	 Headings. 

The captions to the several Articles and Sections hereof are not a part of this Agreement, but are included merely for
convenience of reference only and shall not affect its meaning or interpretation. 

  
 13 

	5.15	 Certain Definitions. 

“$” or “dollar” means U.S. dollars. 

“Agreement” has the meaning set forth in the preamble to this Agreement. 

“Audited Financial Statements” has the meaning set forth in Section 3.9 of this Agreement. 

“Beneficial Ownership” has the meaning set forth in Rule 13d-3
of the Exchange Act. The terms “Beneficial Owner,” “Beneficially Own,” and “Beneficially Owned” shall have the correlative meanings. 

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday
in the United States or Japan, or any day on which banking institutions in the State of New York or Tokyo, Japan are authorized or required by law or other governmental action to close. 

“Buyer” has the meaning set forth in the preamble of this Agreement. 

“Closing” has the meaning set forth in Section 2.1 of this Agreement. 

“Closing Date” has the meaning set forth in Section 2.1 of this Agreement. 

“Common Stock” means the shares of common stock, par value $0.001 per share, of the Company. 

“Company” has the meaning set forth in the preamble to this Agreement. 

“Contract” means any loan or credit agreement, note, bond, mortgage, indenture, lease, sublease,
purchase order, instrument, permit, concession, franchise, license, commitment, contract, subcontract or other agreement, in each case, whether written or oral. 

“Exchange Act” means the Securities Exchange Act of 1934. 

“GAAP” means U.S. generally accepted accounting principles. 

“Governmental Entity” means any domestic or foreign federal, state, municipal, or other governmental
department, commission, board, bureau, agency or instrumentality, or any court or tribunal. 
 “Interim Financial
Statements” has the meaning set forth in Section 3.9 of this Agreement. 
 “Investor Rights
Agreement” has the meaning set forth in Section 2.2 of this Agreement. 

“Liabilities” mean any liabilities or obligations, whether known or unknown, asserted or unasserted,
absolute or contingent, accrued or unaccrued, liquidated or unliquidated, and whether due or to become due, regardless of when asserted. 

“Lien” means any security interest, pledge, lien, bailment (in the nature of a pledge or for purposes
of security), mortgage, deed of trust, the grant of a power to confess judgment, conditional sale or title retention agreement (including any lease in the nature thereof), charge, encumbrance, easement, reservation, restriction, cloud, right of
first refusal or first offer, option, commitment or other similar arrangement or interest in real or personal property, whether oral or written. 

  
 14 

 “Material Adverse Effect” means a material adverse effect
on the business, properties, operations, assets, condition (financial or otherwise) or operating results of the Company and the Subsidiaries, taken as a whole. 

“Material Adverse Effect on Buyer” means a material adverse effect on the business, properties,
operations, assets, condition (financial or otherwise) or operating results of the Buyer. 
 “Material
Agreement” has the meanings set forth in Section 3.7 of this Agreement. 
 “Organizational
Document” means, with respect to a Person (other than an individual), any document by which such Person establishes its legal existence or which governs such Person’s internal affairs. 

“Parties” has the meaning set forth in the preamble to this Agreement. 

“Permits” means all permits, licenses, authorizations, registrations, franchises, approvals, consents,
certificates, variances and similar rights obtained, or required to be obtained, from Governmental Entities. 

“Person” means and includes an individual, a partnership, a corporation, a limited liability company,
an association, a joint stock company, a trust, a joint venture, an unincorporated organization, or a Governmental Entity (or any department, agency, or political subdivision thereof). 

“Proceeding” means any action, suit, proceeding, complaint, charge, hearing, inquiry or investigation
before or by a Governmental Entity or an arbitrator. 
 “SEC” has the meaning set forth in
Section 3.4 of this Agreement. 
 “SEC Reports” means the Company’s reports, schedules,
forms, statements and other documents filed by it under the Exchange Act since January 1, 2017 to the date hereof, including pursuant to Section 13(a) or 15(d) thereof. 

“Securities Act” has the meaning set forth in Section 1.3(a) of this Agreement. 

“Shares” means an aggregate of 12,000,000 shares of Common Stock. 

“Statement Date” has the meaning set forth in Section 3.9 of this Agreement. 

“Subscription Amount” means $21,100,000.00. 

“Subsidiaries” means ABT Holding Company, a Delaware corporation, Advanced Biotherapeutics, Inc., a
Delaware corporation, Athersys Limited, a United Kingdom company, ReGenesys LLC, a Delaware limited liability company, ReGenesys BVBA, a Belgium company, and ReGenesys EU NV, a Belgium company. 

  
 15 

 “Tax” as used in this Agreement, means, with respect to
any Person, (a) all income taxes (including any tax on or based upon net income, gross income, income as specially defined, earnings, profits or selected items of income, earnings or profits) and all gross receipts, sales, use, ad valorem,
transfer, franchise, license, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property or windfall profits taxes, alternative or add-on minimum taxes, customs duties and other
taxes, fees, assessments or charges of any kind whatsoever, together with all interest and penalties, additions to tax and other additional amounts imposed by any taxing authority (domestic or foreign) on such Person (if any) and (b) any
liability for the payment of any amount of the type described in clause (a) above as a result of being a “transferee” (within the meaning of Section 6901 of the Internal Revenue Code of 1986, as amended, or any other applicable
law) of another entity or a member of an affiliated or combined group. 
 “Transaction Documents”
means this Agreement, the Investor Rights Agreement and the Warrant. 
 “Transfer Agent” means
Computershare, Inc. 
 “Warrant” means the warrant to purchase up to 20,000,000 shares of Common
Stock, substantially in the form attached hereto as Exhibit A. 
 “Warrant Shares”
means the shares of Common Stock issuable upon exercise of the Warrant. 
  

	5.16	 Incorporation of Schedules and Exhibits. 

The schedules and exhibits identified in this Agreement are incorporated herein by reference and made a part hereof. 

  
 16 

	5.17	 Rules of Construction. 

The term “this Agreement” means this agreement together with all schedules and the exhibits hereto, as
the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. In this Agreement, the term “the Company’s knowledge” or “the knowledge of the
Company” means the knowledge of each officer of the Company, which could have been acquired after making such reasonable due inquiry and exercising such reasonable diligence as a prudent business person could have made or exercised in
the management of his or her business affairs, including reasonable due inquiry of those key employees and professionals of the Company who could reasonably be expected to have actual knowledge of the matters in question. Accounting terms used but
not otherwise defined herein shall have the meanings given to them under GAAP. The use in this Agreement of the term “including” means “including, without limitation.” The words
“herein,” “hereof,” “hereunder” and other words of similar import refer to this Agreement as a whole, including the schedules and exhibits, as the same may from time to time be
amended, modified, supplemented or restated, and not to any particular section, subsection, paragraph, subparagraph or clause contained in this Agreement. All references to sections, schedules and exhibits mean the sections of this Agreement and the
schedules and exhibits attached to this Agreement, except where otherwise stated. The title of and the section and paragraph headings in this Agreement are for convenience of reference only and shall not govern or affect the interpretation of any of
the terms or provisions of this Agreement. Any reference made in this Agreement to any statute or statutory provision or to any accounting standard means such statute, statutory provision or accounting standard as in effect at such time, or to any
successor statute, statutory provision or accounting standard relating to the same subject as the statute, statutory provision or accounting standard so referred to in this Agreement, and to any then-applicable rules or regulations promulgated
thereunder. The use herein of the masculine, feminine or neuter forms shall also denote the other forms, and words imparting the singular number only shall include the plural and vice versa, as in each case the context may require or permit. Where
specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. The language
used in this Agreement has been chosen by the Parties to express their mutual intent, and no rule of strict construction shall be applied against any Party. 

  
 17 

	5.18	 Severability. 

In the event that any provision of this Agreement is determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of this Agreement shall remain in full force and effect without such provision. In such event, the Parties hereto shall in good faith attempt to negotiate a substitute clause for any provision declared invalid or
unenforceable, which substitute clause shall most nearly approximate the intent of the Parties hereto in agreeing to such invalid provision, without itself being invalid. 

[Signature pages follow.] 

  
 18 

 IN WITNESS WHEREOF, the Company and Buyer have caused their duly authorized
representatives to execute this Agreement as of the date first above written. 
  

			
	ATHERSYS, INC.
		
	 By:
	 	 /s/ Gil Van Bokkelen

		 	 Name: Gil Van Bokkelen

		 	 Title:   Chairman & CEO

  
 [Signature Page
to Securities Purchase Agreement] 

 IN WITNESS WHEREOF, the Company and Buyer have caused their duly authorized
representatives to execute this Agreement as of the date first above written. 
  

			
	HEALIOS K.K.
		
	 By:
	 	 /s/ Hardy TS Kagimoto

		 	 Name: Hardy TS Kagimoto

		 	 Title:   President & CEO

  
 [Signature Page
to Securities Purchase Agreement] 

 Schedule 3.6(a)(i) 

Capitalization of the Company - Authorized Capital Stock (pre-Closing) 

 

			
	 Common Stock, par value $0.001 per share

 
	  	
300,000,000 shares
  

	 Preferred Stock, par value $0.001 per share

 
	  	
10,000,000 shares
  

  
 S-1 

 Schedule 3.6(a)(ii) 

Capitalization of the Company - Issued and Outstanding Capital Stock (pre-Closing) 

 

			
	 Common Stock, par value $0.001 per

share
	  	
125,830,331 shares issued and outstanding

	 Preferred Stock, par value $0.001 per

share
	  	
No shares issued and outstanding

  
 S-2 

 Schedule 3.6(b) 

Outstanding Warrants, Options, Rights, Agreements, etc. 

Shares of Common Stock issuable pursuant to: 
  

	 	•	 	 The Athersys, Inc. Amended and Restated 2007 Long-Term Incentive Plan. 

 

	 	•	 	 The Athersys, Inc. Equity Incentive Compensation Plan. 

 

	 	•	 	 The settlement agreement, dated as of October 12, 2017, between Athersys, Inc. and Garnet
BioTherapeutics, Inc. 

  

	 	•	 	 The common stock purchase agreement, dated as of December 17, 2015, between Athersys, Inc. and Aspire
Capital Fund, LLC. 

  

	 	•	 	 The common stock purchase agreement, dated as of February 1, 2018, between Athersys, Inc. and Aspire
Capital Fund, LLC. 

  
 S-3 

 Schedule 3.10 

Changes 
 None. 

  
 S-4 

 Exhibit A 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY OTHER APPLICABLE SECURITIES LAWS OR AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE SECURITIES LAWS. 

COMMON STOCK PURCHASE WARRANT 

ATHERSYS, INC. 
 Issue Date:
March [●], 2018 (the “Issue Date”) 
 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value
received, HEALIOS K.K. (“Healios”), or its permitted assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Issue Date and on or prior to the close of business on September 1, 2020 (subject to adjustment pursuant to Section 5(l), the “Termination Date”), but not thereafter, to purchase from Athersys, Inc., a Delaware
corporation (the “Company”), up to 20,000,000 shares (subject to the limitations contained herein, including Section 3(d), and subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common
stock, par value $0.001 per share (the “Common Stock”). The purchase price of one Warrant Share shall be equal to the applicable exercise price set forth in Section 1(b) (each such price, as applicable, the “Exercise
Price”). This Warrant is being issued pursuant to that certain Securities Purchase Agreement, dated as of March 13, 2018 (as may be amended from time to time, the “Purchase Agreement”), between Healios and the Company.
Healios and the Company are also parties to that certain Investor Rights Agreement, dated as of March [●], 2018 (as may be amended from time to time, the “Investor Rights Agreement”), and that certain Letter of Intent for
Collaboration Expansion, dated as of March 13, 2018 (as may be amended from time to time, the “LOI”), pursuant to which Healios and the Company intend to enter into a collaboration expansion agreement substantially in the form
attached thereto (as may be amended from time to time, the “Collaboration Agreement”). 
 As used in this
Warrant, (a) an “Affiliate” means, with respect to any Person, any other Person who, directly or indirectly, controls, is controlled by, or under common control with such Person; for purposes of this definition, the term
“control” (including the correlative meanings of the terms “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the
power to direct or cause the direction of the management policies of such Person, whether through the ownership of voting securities or by contract or otherwise, (b) a “Business Day” means any day excluding Saturday, Sunday or
any day which is a legal holiday under the laws of the State of New York or of Tokyo, Japan, or a day on which banking institutions are authorized or required by law or other governmental action to close, (c) “Capital Stock” means,
with respect to any Person, (i) any capital stock of such Person, (ii) any security convertible, with or without consideration, into any capital stock of such Person, (iii) any other shares, interests, rights to purchase, warrants,
options, participations or other equivalents of or interests in (however designated) the capital stock of such Person and (iv) any other equity interest in, or right to vote generally in elections of directors or the comparable governing body
of, such Person, (d) a “Person” means any individual, partnership, corporation, limited liability company, association, joint stock company, trust, joint venture, unincorporated organization or governmental entity (or any
department, agency, or political subdivision thereof) and (e) a “Trading Day” means any day on which the The Nasdaq Stock Market, LLC is open for trading. 

 Section 1.    Vesting; Exercisability; Exercise Price. The
Holder’s right to exercise this Warrant with respect to the Warrant Shares is subject to vesting and limitations on exercisability as follows: 

(a)    Except as set forth below in Section 1(b)(ii), this Warrant will become exercisable on the
later of (i) June 1, 2018 and (ii) the first date that Healios has satisfied the $2.5 million payment obligations set forth in Section 7.2(a) of the Collaboration Agreement. Accordingly, except as set forth below in
Section 1(b)(ii),in no event will this Warrant be exercisable unless such $2.5 million payment has been made. 

(b)    Subject to Section 1(a) and subject to any adjustment required by Section 3: 

(i)    this Warrant may be exercised at the Exercise Price per Warrant Share with respect to 6,000,000
Warrant Shares in the aggregate as follows: 
 (A)    during the period from June 1, 2018 through
December 31, 2018, Holder may exercise this Warrant with respect to no more than 1,500,000 Warrant Shares at an Exercise Price of $2.50 per Warrant Share; 

(B)    during the period from September 1, 2018 through March 31, 2019, Holder may exercise
this Warrant with respect to no more than 1,500,000 Warrant Shares at an Exercise Price of $2.75 per Warrant Share; 

(C)    during the period from January 1, 2019 through June 30, 2019, Holder may exercise this
Warrant with respect to no more than 1,500,000 Warrant Shares at an Exercise Price of $3.00 per Warrant Share; and 

(D)    during the period from April 1, 2019 through September 30, 2019, Holder may exercise
this Warrant with respect to no more than 1,500,000 Warrant Shares at an Exercise Price of $3.25 per Warrant Share; 

(ii)    this Warrant may be exercised at an Exercise Price per Warrant Share equal to the greater of
$1.76 and the Reference Price with respect to no more than 4,000,000 Warrant Shares during the period beginning on the later of (A) the date that the Collaboration Agreement has been entered into and (B) the date that the
$10.0 million held in escrow as contemplated by the LOI is released to the Company, through September 1, 2020; and 

  
 2 

 (iii)    this Warrant may be exercised at the Exercise Price
per Warrant Share with respect to 10,000,000 Warrant Shares in the aggregate as follows: 

(A)    during the period from June 1, 2018 through August 31, 2018, Holder may exercise this
Warrant at an Exercise Price per Warrant Share equal to the greater of $2.50 and the Reference Price; 

(B)    during the period from September 1, 2018 through November 30, 2018, Holder may exercise
this Warrant at an Exercise Price per Warrant Share equal to the greater of $2.75 and the Reference Price; 

(C)    during the period from December 1, 2018 through February 28, 2019, Holder may exercise
this Warrant at an Exercise Price per Warrant Share equal to the greater of $3.00 and the Reference Price; 

(D)    during the period from March 1, 2019 through May 31, 2019, Holder may exercise this
Warrant at an Exercise Price per Warrant Share equal to the greater of $3.25 and the Reference Price; 

(E)    during the period from June 1, 2019 through August 31, 2019, Holder may exercise this
Warrant at an Exercise Price per Warrant Share equal to the greater of $3.50 and the Reference Price; 

(F)    during the period from September 1, 2019 through November 30, 2019, Holder may exercise
this Warrant at an Exercise Price per Warrant Share equal to the greater of $3.75 and the Reference Price; 

(G)    during the period from December 1, 2019 through February 29, 2020, Holder may exercise
this Warrant at an Exercise Price per Warrant Share equal to the greater of $4.00 and the Reference Price; and 

(H)    during the period from March 1, 2020 through September 1, 2020, Holder may exercise this
Warrant at an Exercise Price per Warrant Share equal to the greater of $4.25 and the Reference Price. 
 As used in this
Warrant, “Reference Price”, means 110% of the average closing price per share of the Common Stock for the ten (10) Trading Days ending on the trading day immediately preceding (and not including) the Exercise Date, as reported
on The Nasdaq Stock Market, LLC (or in the event the Common Stock is no longer listed or traded on any Nasdaq stock exchange, then on the principal stock exchange or market on which the Common Stock is listed or traded, including any of the OTC
Markets). 
 (c)    Subject to any adjustment required by Section 3, notwithstanding anything to
the contrary in this Warrant, in no event shall this Warrant be exercisable for more than 20,000,000 Warrant Shares. 

  
 3 

 Section 2.    Exercise. 

(a)    Subject to Section 1, exercise of the purchase rights represented by this Warrant with
respect to Warrant Shares may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice
in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly completed and executed copy of a notice of exercise substantially in the form attached hereto as Exhibit A (a “Notice of
Exercise”). The date on which such delivery shall have taken place (or be deemed to have taken place) shall be referred to herein as the “Exercise Date”. Within seven (7) Trading Days following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank; provided, however, in the event that
the Holder has not delivered such aggregate Exercise Price within seven (7) Trading Days following the date of such exercise as aforesaid, the Company shall not be obligated to deliver such Warrant Shares hereunder until such payment is made.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to
the contrary, subject to Section 5(k), the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Business Days after the relevant event shall have occurred. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within two (2) Business Days of receipt of such notice, including any
objection to the Holder’s calculation of the Reference Price (as defined in Section 1(b)). The Holder, by acceptance of this Warrant, acknowledges and agrees that, by reason of the provisions of this paragraph, following the purchase of
a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 

(b)    Mechanics of Exercise. 

(i)    Delivery of Warrant Shares Upon Exercise. Upon each exercise of this Warrant, the Company
shall promptly, but in no event later than seven (7) Trading Days after delivery of the applicable Notice of Exercise (subject to delivery by the Holder to the Company of the aggregate Exercise Price payable pursuant to Section 1(b)),
instruct the transfer agent for the Common Stock (the “Transfer Agent”) to record the issuance of the Warrant Shares purchased hereunder to Holder in book-entry form pursuant to the Transfer Agent’s regular procedures. The
Warrant Shares shall be deemed to have been issued, and the Holder shall be deemed to have become a holder of record of such shares for all purposes, as of the Exercise Date with payment to the Company of the Exercise Price having been paid. 

  
 4 

 (ii)    Rescission Rights. If the Company fails to
issue or cause to have issued the Warrant Shares pursuant to Section 2(b)(i) within seven (7) Trading Days after delivery of the applicable Notice of Exercise, then the Holder will have the right to rescind such exercise. The right of
rescission of the Holder under this Section 2(b)(ii) is subject to delivery by the Holder of the aggregate Exercise Price payable pursuant to Section 1(b). 

(iii)    No Fractional Shares or Scrip. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. 

(iv)    Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to
the Holder for any issue, transfer, stamp or other tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name
of the Holder. Without limiting the generality of the foregoing, the Company shall pay all fees required for same-day processing of any Notice of Exercise. 

(v)    Closing of Books. The Company will not close its stockholder books or records in any manner
which prevents the timely exercise of this Warrant, pursuant to the terms hereof. 

(c)    Holder’s Exercise Limitations. The Company shall not effect any exercise of this
Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of
Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own shares of Common Stock in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company subject to a limitation on conversion or exercise that results in such securities or the
Common Stock underlying such securities not being beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(c), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in
the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no
liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance
with the Beneficial Ownership Limitation. For purposes of this Section 2(c), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such
number of outstanding shares of Common Stock was reported. As used in this Warrant, “Beneficial Ownership Limitation” means 19.9% of the number of shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant. The provisions of this Section 2(c) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(c) to
correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. 

  
 5 

 Section 3.    Certain Adjustments. 

(a)    Stock Dividends, Subdivision, Combinations and Consolidations. If the Company, at any time
while this Warrant is outstanding (in whole or in part): (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock (or other class of Capital Stock of the Company then issuable upon exercise of this
Warrant) or any other equity or equity equivalent securities payable in shares of Common Stock (or such other class of Capital Stock) (which, for avoidance of doubt, shall not include any shares of Common Stock (or such other class of Capital Stock)
issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock (or other class of Capital Stock of the Company then issuable upon exercise of this Warrant) into a larger number of shares or
(iii) combines or consolidates (including, without limitation, by reverse stock split) outstanding shares of Common Stock (or other class of Capital Stock of the Company then issuable upon exercise of this Warrant) into a smaller number of
shares, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares
of Common Stock outstanding immediately after such event; with respect to Section 1(b), the number of Warrant Shares issuable at certain specified Exercise Prices shall be multiplied by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event; and the total number of shares issuable upon exercise of this
Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or consolidation. If the Company, at any time while this
Warrant is outstanding (in whole or in part) distributes rights on shares of its Common Stock (or other class of Capital Stock of the Company then issuable upon exercise of this Warrant) in connection with a shareholder rights plan, no adjustment
shall be made pursuant to this Section 3 and any such rights shall accompany the Warrant Shares issued pursuant to this Warrant if such shareholder rights plan remains in effect. 

  
 6 

 (b)    Reclassifications, Reorganizations, Consolidations
and Mergers. In the event of (i) any capital reorganization of the Company, (ii) any reclassification or recapitalization of the stock of the Company (other than (x) a change in par value or from par value to no par value or from
no par value to par value or (y) as a result of a stock dividend, subdivision, combination or consolidation of shares as to which Section 3(a) shall apply) or (iii) any consolidation or merger of the Company with or into another
Person (where the Company is not the surviving corporation or where there is a change in or distribution with respect to the Common Stock or any other class of Capital Stock then issuable upon exercise of this Warrant), this Warrant shall, after
such reorganization, reclassification, recapitalization, consolidation or merger, be exercisable for the kind and number of shares of stock or other securities or property (“Alternate Consideration”) of the Company or of the
successor corporation resulting from such consolidation or surviving such merger, if any, to which the holder of the number of Warrant Shares underlying this Warrant (at the time of such reorganization, reclassification, recapitalization,
consolidation or merger, and subject to the limitations set forth in Section 1 and Section 2) would have been entitled upon such reorganization, reclassification, recapitalization, consolidation or merger. In such event, the aggregate
Exercise Price otherwise payable for the shares of Common Stock (or such other class of Capital Stock) issuable upon exercise of this Warrant shall be allocated among the Alternative Consideration receivable as a result of such reorganization,
reclassification, recapitalization, consolidation, or merger in proportion to the respective fair market values of such Alternate Consideration. If and to the extent that the holders of Common Stock (or such other class of Capital Stock) have the
right to elect the kind or amount of consideration receivable upon consummation of such reorganization, reclassification, recapitalization, consolidation or merger, then the consideration that the Holder shall be entitled to receive upon exercise
shall be specified by the Holder, which specification shall be made by the Holder by the later of (A) ten (10) Business Days after the Holder is provided with a final version of all material information concerning such choice as is provided to
the holders of Common Stock (or such other class of Capital Stock), and (B) the last time at which the holders of Common Stock (or such other class of Capital Stock) are permitted to make their specifications known to the Company;
provided, however, that if the Holder fails to make any specification within such time period, the Holder’s choice shall be deemed to be whatever choice is made by a plurality of all holders of Common Stock (or such other class of
Capital Stock) that are not affiliated with the Company (or, in the case of a consolidation or merger, any other party thereto) and affirmatively make an election (or of all such holders if none of them makes an election). From and after any such
reorganization, reclassification, recapitalization, consolidation or merger, all references to “Warrant Shares” herein shall be deemed to refer to the Alternate Consideration to which the Holder is entitled pursuant to this
Section 3(b). The provisions of this clause shall similarly apply to successive reorganizations, reclassifications, recapitalizations, consolidations, or mergers. 

  
 7 

 (c)    Other Distributions. During such time as this
Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) other than any dividend or
distribution referred to in Sections 3(a) or (b) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that
the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
participation in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completed exercised at the time of such
Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant. 

(d)    Calculations. All calculations under this Section 3 shall be made to the nearest cent
or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock (or such other Company security as is then issuable upon exercise of this Warrant) deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (or such other Company security) (excluding treasury shares, if any) issued and outstanding on such date. 

(e)    Notice to Holder. 

(i)    Adjustment to Terms of Warrant. Whenever any of the terms of this Warrant are adjusted
pursuant to any provision of this Section 3 or any other applicable provision hereof, the Company shall promptly send to the Holder a notice signed by a duly authorized officer of the Company and setting forth (x) the Exercise Price,
number of Warrant Shares and, if applicable, the kind and amount of Alternate Consideration purchasable hereunder after such adjustment and (y) the facts requiring such adjustment in reasonable detail. 

  
 8 

 (ii)    Notice to Allow Exercise by Holder. If,
during the period in which this Warrant is outstanding, (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of
any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the
Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of
the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to
become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Securities and Exchange Commission (the “SEC”) pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. 

Section 4.    Transfer of Warrant and Warrant Shares. 

(a)    Restrictive Legend.    The Warrant Shares (unless and until registered
under the Securities Act of 1933, as amended (the “Securities Act”), or transferred pursuant to Rule 144 promulgated under the Securities Act, or any successor rule or regulation hereafter adopted by the SEC, as such rule may be
amended from time to time (“Rule 144”)) will be stamped or imprinted with a legend in substantially the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT UNDER
ANY CIRCUMSTANCES BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY OTHER APPLICABLE SECURITIES LAWS OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE SECURITIES LAWS. 
  

  
 9 

 (b)    Transferability. Healios and any subsequent
Holder shall not sell, assign, transfer, pledge or dispose of any portion of this Warrant, by operation of law or otherwise, without the prior written consent of the Company, other than the transfer of this Warrant in its entirety to any Affiliate
of Healios, which may be conducted without consent provided that an assignment form substantially in the form attached hereto as Exhibit B is duly completed and executed by any such subsequent Holder. Upon any permitted transfer of this
Warrant in full, the Holder shall be required to physically surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. The Company shall not assign or transfer any part of its obligations under this Warrant without the
prior written consent of Healios, except in a consolidation or merger described in Section 3(b). 

(c)    Investor Rights Agreement; Warrant Register. 

(i)    All Warrant Shares issuable upon exercise of this Warrant will be subject to the rights and
obligations under the Investor Rights Agreement, including, without limitation, such Warrant Shares being Registrable Securities (as defined in the Investor Rights Agreement). 

(ii)    The Company shall register this Warrant upon records to be maintained by the Company for that
purpose (the “Warrant Register”) in the name of the record Holder hereof from time to time. Absent manifest error or actual notice to the contrary, the Company may deem and treat the Holder of this Warrant so registered as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes. 

Section 5.    Miscellaneous. 

(a)    No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(b). 

(b)    Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon delivery
by the Holder to the Company of (a) notice of the loss, theft, destruction or mutilation of this Warrant and (b) in the case of loss, theft or destruction, an indemnity agreement in a form and amount reasonably satisfactory to the Company
or, in the case of mutilation, surrender of the mutilated Warrant, the Company will make and deliver a new Warrant of like tenor dated as of the Issue Date. 

(c)    Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. 

  
 10 

 (d)    Authorized Shares. The Company covenants that,
during the period this Warrant is exercisable (in whole or in part), it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any national securities exchange upon which the Common Stock. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and full payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable, not subject to
any preemptive rights and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than pursuant to the Investor Rights Agreement and taxes in respect of any transfer occurring contemporaneously with such
issue). 
 (e)    Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of New York without giving effect to the principles of conflict of laws thereof. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

(f)    Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on
the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. 

(g)    Notices. Any notice, request or other document required or permitted to be given or
delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Investor Rights Agreement. 

(h)    Limitation of Liability. No provision hereof, in the absence of any affirmative action by
the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the
Company, whether such liability is asserted by the Company or by creditors of the Company. 

(i)    Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights
and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any
Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. 

(j)    Amendment. This Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder. 

  
 11 

 (k)    Termination. This Warrant, and all rights,
obligations and liabilities hereunder, shall be automatically terminated upon the earliest of (i) (A) the termination of the Collaboration Agreement by the Company (or any of its subsidiaries) pursuant to Section 8.2 thereof or
(B) the termination of any other license agreement and/or collaboration agreement between the Company (or any of its subsidiaries) and Healios in effect as of the Issue Date or entered into pursuant to the terms of the Collaboration Agreement,
in each case in accordance with the terms of such agreement and as a result of an uncured breach by Healios that has triggered such termination; provided, that this Warrant shall not terminate pursuant to Section 5(k)(i)(B) unless the
Company provides Healios with written notice of the applicable breach, and Healios does not either cure such breach within the cure period provided for in the applicable agreement or reach an agreement with the Company (both parties negotiating in
good faith), within 30 days of receipt of such notice, to adequately compensate the Company for such breach, (ii) July 1, 2018, if Healios has not satisfied the $2.5 million payment obligations set forth in Section 7.2(a) of the
Collaboration Agreement by such date and (iii) the date immediately following the Termination Date (subject to any Notice of Exercise pending at the Termination Date, in which case such date shall be the date immediately after the date that the
Company delivers the Warrant Shares that were subject to such pending Notice of Exercise). Upon termination of this Warrant, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Business Days after the
relevant termination event shall have occurred. 
 (l)    Extension. In the event that, in
connection with the clinical trial being conducted in Japan by or on behalf of Healios and referred to by Healios and the Company as the “TREASURE” study (referenced in Section 6.2 of the form of Collaboration Agreement attached to
the LOI), the Company fails to provide adequate MultiStem product supply to Healios to dose 220 patients by December 31, 2018, then the Termination Date will automatically be extended to the date that is the
24-month anniversary of the date on which such adequate supply is delivered, and the end dates contained in Section 1(b)(ii) and Section 1(b)(iii)(H) will be automatically extended to the new
Termination Date. 
 (m)    Severability. Wherever possible, each provision of this Warrant
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition
or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 

(n)    Headings. The headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant. 
 [Signatures Contained on the Following Page] 

  
 12 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized as of the Issue Date. 
  

			
	ATHERSYS, INC.

  

			
	 By:
	 	  

		 	 Name:

		 	 Title:

  
 [Signature Page to
Warrant] 

 EXHIBIT A 

NOTICE OF EXERCISE 

TO:    ATHERSYS, INC. 

Reference is made to that certain Common Stock Purchase Warrant (the “Warrant”) issued by Athersys, Inc. (the
“Company”) on _______ __, 2018 Capitalized terms used but not otherwise defined herein shall the respective meanings give thereto in the Warrant. 

(1) The undersigned Holder of the Warrant hereby elects to exercise the Warrant for ______ Warrant Shares pursuant to
Section 1(b)__ of the Warrant, subject to delivery of the aggregate Exercise Price for the Warrant Shares as to which the Warrant is so exercised and the undersigned Holder hereby instructs the Company to issue the applicable number of Warrant
Shares in the name of the undersigned Holder. 
 (2) The undersigned Holder of the Warrant represents and warrants to the
Company that, as of the date hereof, Holder’s calculation of the Reference Price is $____ per Warrant Share. 
 (3)
The undersigned Holder hereby represents and warrants to the Company that, as of the date hereof: 

a)    Experience; Accredited Investor Status. The Holder (i) is an accredited
investor as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act, (ii) is capable of evaluating the merits and risks of its investment in the Company, (iii) has the capacity to protect its own interests,
and (iii) has the financial ability to bear the economic risk of its investment in the Company. 

b)    Company Information. The Holder has been provided access to all information
regarding the business and financial condition of the Company, its expected plans for future business activities, material contracts, intellectual property, and the merits and risks of its purchase of the Warrants Shares, which it has requested or
otherwise needs to evaluate an investment in the Warrant Shares. It has had an opportunity to discuss the Company’s business, management and financial affairs with directors, officers and management of the Company and has had the opportunity to
review the Company’s operations and facilities. It has also had the opportunity to ask questions of, and receive answers from, the Company and its management regarding the terms and conditions of this investment and all such questions have been
answered to its satisfaction. 
 c)    Investment. The Holder has not been formed
solely for the purpose of making this investment and is acquiring the Warrant Shares for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution of any part thereof. It
understands that the Warrant Shares have not been registered under the Securities Act or applicable state and other securities laws and are being issued by reason of a specific exemption from the registration provisions of the Securities Act and
applicable state and other securities laws, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of its representations as expressed herein. 

d)    Transfer Restrictions. The Holder acknowledges and understands that
(i) transfers of the Warrant Shares are subject to transfer restrictions under the federal securities laws and the Investor Rights Agreement and (ii) it may have to bear the economic risk of this investment for an indefinite period of time
unless the Warrant Shares are subsequently registered under the Securities Act and applicable state and other securities laws or unless an exemption from such registration is available. 

 

			
	 Name of Registered Owner:
	 	  

			
	 Signature of Authorized Signatory of Registered Owner:
	 	  

			
	 Name of Authorized Signatory:
	 	  

			
	 Title of Authorized Signatory:
	 	  

			
	 Date:
	 	  

 EXHIBIT B 

ASSIGNMENT FORM 

  1.                (To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.) 

  2.                FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to the undersigned assignee. Such assignee hereby acknowledges, agrees and confirms by its signature below that, from and after the date hereof, it will be bound by the terms and
conditions of the foregoing Warrant. 

  3.                Such assignee further
acknowledge, agrees and confirms by its signature below that, from and after the date hereof, it shall be joined to that certain Investor Rights Agreement, dated March [●], 2018, by and between Athersys, Inc. and Healios, K.K. (the
“Investor Rights Agreement”), as the Investor, and shall be subject to all of the applicable rights, restrictions, conditions, duties and obligations set forth therein. Any notices required or permitted to be delivered to such
assignee pursuant to the Investor Rights Agreement shall be delivered to the address set forth below. 
  

			
	 Assignee Name:
	  	  

		  	 (Please Print)

		
	 Assignee Address:
	  	  

		  	 (Please Print)

		
	 Dated:
                                 ,
            
	  	
		
	 Holder’s Signature:
                              
	  	
		
	 Holder’s Address:EX-10.2

 Exhibit 10.2 

INVESTOR RIGHTS AGREEMENT 

THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of March 14, 2018, between
Athersys, Inc., a Delaware corporation (the “Company”), and HEALIOS K.K. (the “Investor”). 

RECITALS 

A. On March 13, 2018, the Company and the Investor entered into a Securities Purchase Agreement (the “Purchase
Agreement”), which provides for the issuance and sale to the Investor of (i) 12,000,000 shares (the “Shares”) of Common Stock and (ii) a warrant (the “Warrant”) to purchase up to 20,000,000 shares of
Common Stock (the “Warrant Shares”). 
 B. As an inducement to entering into the Purchase Agreement, the
Investor and the Company hereby agree that this Agreement will govern certain rights of the Investor and the Company related to the Shares and the Warrant Shares. 

C. The parties agree as follows: 

1.    Definitions. Unless otherwise provided, all capitalized terms have the meaning given to them
in this Section 1. For purposes of this Agreement: 
 (a)    “Affiliate” means,
with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by or is under common control with such Person. For purposes of this definition, the term “control” (including the correlative
meanings of the terms “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of
such Person, whether through the ownership of voting securities or by contract or otherwise. 

(b)    “beneficially own” has the meaning given to such term under Rule 13d-3 of the Exchange Act; provided that, for purposes of this Agreement, the number of shares of Common Stock beneficially owned by the Investor and the Investor Affiliates at any given time
shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the then-nonexercised portion of the Warrant beneficially owned by the Investor or any of the Investor Affiliates and (ii) exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Investor or any of the Investor
Affiliates. 
 (c)    “Beneficial Ownership Limitation” has the meaning given to such
term in the Warrant. The provisions of Section 2(c) of the Warrant shall apply to this Agreement in connection with making any calculation of, or other determination with respect to, the Beneficial Ownership Limitation. 

(d)    “Blackout Period” has the meaning given to such term under Section 4.1(b) of
this Agreement. 

 (e)    “Business Day” means any day except
any Saturday, any Sunday, any day which is a federal legal holiday in the United States or Japan, or any day on which banking institutions in the State of New York or Tokyo, Japan are authorized or required by law or other governmental action to
close. 
 (a)    “Change of Control” means any of the following events: (i) any
Person or group of Persons is or becomes the beneficial owner, directly or indirectly, of a majority of the total voting power represented by all then-outstanding Common Stock, (ii) the Company consolidates with or merges into another Person,
or any Person consolidates or merges into the Company, other than (A) a merger or consolidation which would result in the Securities (as defined in Section 3.1) outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the Securities or such surviving entity or any parent thereof
outstanding immediately after such merger or consolidation or (B) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person becomes the beneficial owner, directly or
indirectly, of a majority of the total voting power of all then-outstanding Securities, (iii) the Company conveys, transfers or leases all or substantially all of its assets to any Person other than a wholly owned Affiliate of the Company, or
(iv) individuals who constitute Continuing Directors cease for any reason to constitute at least a majority of the Company Board. 

(b)    “Closing Date” means the date of the closing of the sale of the Shares and
Warrant under the Purchase Agreement. 
 (c)    “Collaboration Agreement” means the
Collaboration Expansion Agreement contemplated by the Letter of Intent for Collaboration Expansion, which Letter of Intent is dated as of the date hereof, between the Company and the Investor. 

(d)    “Common Stock” means the shares of common stock, par value $0.001 per share, of
the Company or, in the event of any capital reorganization of the Company, any reclassification or recapitalization of the stock of the Company, or any consolidation or merger of the Company with or into another Person where the Company is not the
surviving corporation, the kind of equity securities of the Company or of the successor corporation that holders of Common Stock prior to such reorganization, reclassification, recapitalization, consolidation or merger hold or otherwise become
entitled to following such reorganization, reclassification, recapitalization, consolidation or merger. 

(e)    “Common Stock Equivalents” means any securities of the Company that would entitle
the holder thereof to acquire Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock. 
 (f)    “Company Board” means the board of
directors of the Company. 
 (g)    “Continuing Directors” means the directors of the
Company on the date hereof, and each other director, if in each case, such other director’s nomination for election to the Company Board was recommended by, or whose appointment to the Company Board was approved by, at least a majority of the
other Continuing Directors. 

  
 2 

 (h)    “Damages” means any joint or several
loss, claim, damage, liability, cost (including, without limitation, reasonable cost of preparation and investigation and reasonable attorney’s fees), and judgment, fine, penalty, charge, or settlement cost in respect of any Proceeding, and
expense to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, claim, damage, liability, cost, judgment, fine, penalty, charge, settlement cost or expense (or any
action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company filed pursuant to the terms of this Agreement, including
any preliminary prospectus or prospectus contained therein or any amendments or supplements thereto, or (ii) an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein (with respect to any preliminary prospectus or prospectus or any amendments or supplements thereto, in the light of the circumstances under which they were made) not misleading. 

(i)    “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(j)    “Form S-3” means such form under the
Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 (k)    “group” means a “group” within the meaning of
Section 13(d)(3) of the Exchange Act. 
 (l)    “Governmental Entity” means any
domestic or foreign federal, state, municipal, or other governmental department, commission, board, bureau, agency or instrumentality, or any court or tribunal. 

(m)    “Investor Affiliate” means any Affiliate of the Investor. 

(n)    “Investor Director” means any director nominee selected by the Investor to the
Company Board. 
 (o)    “Person” means and includes an individual, a partnership, a
corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, or a Governmental Entity (or any department, agency, or political subdivision thereof). 

(p)    “Proceeding” means an action, claim, suit, investigation, inquiry or proceeding
(including, without limitation, an investigation or partial proceeding, such as a deposition) by any judicial, regulatory or self-regulatory Person, whether commenced or threatened. 

  
 3 

 (q)    “Registrable Securities” means
(i) the Shares issued by the Company to the Investor pursuant to the Purchase Agreement, (ii) the Warrant Shares issued by the Company to the Investor pursuant to the Warrant, and (iii) any shares of Common Stock issued to the
Investor pursuant to Section 9.2. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (A) such Registrable Securities have been sold or otherwise disposed of pursuant to an effective
registration statement, or (B) such Registrable Securities have been sold under SEC Rule 144. 

(r)    “SEC” means the United States Securities and Exchange Commission. 

(s)    “SEC Rule 144” means Rule 144 promulgated by the SEC
under the Securities Act (or any successor provision thereto). 
 (t)    “SEC
Rule 415” means Rule 415 promulgated by the SEC under the Securities Act, as such rule may be amended from time to time, or any other similar or successor rule or regulation of the SEC that may at any time permit
the Investor to sell securities of the Company to the public on a registered basis. 

(u)    “Securities Act” means the Securities Act of 1933, as amended. 

(v)    “Selling Expenses” means all underwriting discounts, selling commissions, and
stock transfer taxes applicable to the sale of Registrable Securities and the fees and disbursements of counsel to the Investor in connection with the sale of Registrable Securities. 

(w)    “Termination Date” has the meaning given to such term in the Warrant. 

2.     Voting. Commencing upon the issuance of the Shares to the Investor pursuant to the
Purchase Agreement and continuing thereafter until the end of the Standstill Period (as defined below), the Investor will, and will cause each Investor Affiliate to, (i) cause all Common Stock beneficially owned by the Investor and the Investor
Affiliates that they are entitled to vote at any meeting of stockholders to be present, in person or by proxy, at all meetings of the Company’s stockholders so that such Common Stock will be counted as present for purposes of determining the
presence of a quorum of stockholders at such meeting, and (ii) cause all Common Stock beneficially owned by such Investor and Investor Affiliates that they are entitled to vote at any meeting of stockholders to be voted in favor of the
recommendations of the Company Board with respect to the election of each member of any slate of directors recommended by the Company Board, subject to the Company Board’s recommendation of all Investor nominees designated by the Investor
pursuant to Section 8.3(b). 
 3.     Standstill. 

3.1   As of the date of this Agreement, other than the Shares issued pursuant to the Purchase Agreement and the
Warrant Shares issuable pursuant to the Warrant, the Investor represents that neither the Investor nor any Investor Affiliate beneficially owns any Common Stock or other securities entitled to be voted generally in the election of the Company Board
or any direct or indirect options or other rights to acquire, or securities or other instruments that are convertible into, any such securities (collectively, “Securities”). 

  
 4 

 3.2     The Investor hereby agrees that, for a period
commencing on the date hereof and ending on September 1, 2020 (the “Standstill Period”), it will not, and it will cause each Investor Affiliate and other Persons acting on its behalf or on behalf of any Investor Affiliate not
to, unless invited in writing by the Company Board to take such action, propose or publicly announce or otherwise publicly disclose an intent to propose, or enter into or agree to enter into, singly or with any other Person (other than the Company
or a Company Affiliate) (x) any form of business combination, acquisition, Change of Control transaction or other transaction relating to the Company or any of its Affiliates (other than a partnership or comparable strategic transaction
involving the out-license of one or more of the Company’s products) or (y) any form of restructuring, recapitalization or similar transaction with respect to the Company or any of its Affiliates.

 3.3    During the Standstill Period, the Investor will not, and will cause its Affiliates and other
Persons acting on its behalf not to, directly or indirectly, singly or with any other Person, unless invited in writing by the Company Board to take such action: 

(a)    acquire beneficial ownership of any Securities; provided, however, that Investor and
any Investor Affiliate may acquire (i) Common Stock or Common Stock Equivalents pursuant to Section 9, (ii) Common Stock upon exercise of the Warrant or (iii) Common Stock or Common Stock Equivalents directly from the Company at a
purchase price per share to be agreed upon by the Company; provided further, neither the Investor nor any Investor Affiliate shall be permitted to acquire any shares of Common Stock pursuant to an exercise of the Warrant or otherwise
to the extent that after giving effect to such acquisition, the Investor (together with the Investor Affiliates, and any other Persons acting as a group together with the Investor or any of the Investor Affiliates), would beneficially own shares of
Common Stock in excess of the Beneficial Ownership Limitation; 
 (b)    make a tender, exchange or
other offer to acquire any Securities; 
 (c)    with respect to the Company or its Securities, make,
engage or in any way participate in, directly or indirectly, any “solicitation” (as such term is used in the proxy rules of the SEC) of proxies or consents (whether or not relating to the election or removal of directors), or seek to
advise or influence any third Person with respect to the voting of any Securities; 
 (d)    call or
seek to have called any meeting of the stockholders of the Company, propose or nominate for election to the Company Board any Person or cause any of its Securities to be voted in favor of any Person whose nomination has not been approved by the
Company Board; 
 (e)    initiate, propose or otherwise “solicit” (as such term is used in
the proxy rules of the SEC) stockholders of the Company for the approval of stockholder proposals made to the Company, whether made pursuant to Rule 14a-8 or
Rule 14a-4 under the Exchange Act or otherwise, or cause or encourage or attempt to cause or encourage any other Person to initiate any such stockholder proposal, regardless of its purpose; 

(f)    deposit any Securities in a voting trust or subject any Securities to any arrangement or agreement
with respect to the voting of such Securities; 

  
 5 

 (g)    (i) act in concert with other Persons to take any
action in clauses (a) through (e) above or to form a group with others with respect to any Securities or (ii) enter into discussions, negotiations, arrangements or agreements with others relating to the actions referred to in clauses
(a) through (e) above; 
 (h)    take any action which would reasonably be expected to require the
Company to make a public announcement in respect of any matter contemplated by Section 3.2 or this Section 3.3; or 

(i)    request or propose in writing to the Company Board, any member(s) thereof or any officer of the
Company that the Company amend, waive or consider the amendment or waiver of, any provisions set forth in Section 3.2 or this Section 3.3. 

Notwithstanding anything in Section 3.2 or Section 3.3 to the contrary, the restrictions set forth in
Section 3.2 and Section 3.3 will not apply, solely to the extent necessary to facilitate a public or private offer by the Investor to enter into a Change of Control transaction, upon the earliest to occur of (x) the public
announcement by the Company of its entry into a definitive agreement providing for a Change of Control, (y) as long as the Investor has not violated Section 3.2 or Section 3.3 with respect to such third Person, the public announcement
by a third Person of any tender, exchange or other offer or proposal the consummation of which would result in a Change of Control (an “Acquisition Proposal”) and as to which the Company has not publicly made a recommendation
against such Acquisition Proposal or (z) as long as the Investor has not violated Section 3.2 or Section 3.3 with respect to such third Person, a third Person publicly discloses that it has beneficial ownership of, or has entered into
an agreement that would allow such third Person to acquire shares of Common Stock, in each case in excess of 10.0% of the Common Stock, other than a third Person that is a passive investor that has filed a Schedule 13G with respect to its beneficial
ownership and has not filed a Schedule 13D with respect to such beneficial ownership; provided, however, that if (i) any of the transactions referred to in (a) or (b) terminates and the Company has not made a public
announcement of its intent to solicit or engage in a transaction (or has announced its decision to discontinue pursuing such a transaction) the consummation of which would result in a Change of Control, or (ii) such third Person referred to in
(c) publicly discloses that it no longer beneficially owns more than 10.0% of the Common Stock or that it terminates the agreement referred to in (c) above, then the restrictions contained in Section 3.2 and Section 3.3 will
again be applicable. Furthermore, notwithstanding anything in Section 3.2 or Section 3.3 to the contrary, the Investor will not be prohibited from (1) making a confidential proposal to the Company Board that, on its own, is reasonably
expected to not require the Company to make a public announcement regarding such proposal and (2) entering into discussions with potential capital sources and financial, legal, accounting and other professional advisors that are subject to
confidentiality obligations solely for the purpose of preparing, and to facilitate, a confidential proposal to the Company Board as described in (1) above. 

  
 6 

 4.    Registration Rights. The Company covenants and
agrees as follows: 
 4.1  Registration Rights. 

(a)    At any time after the six-month anniversary of the Closing
Date, upon the written request of the Investor, the Company shall file a registration statement on Form S-3, or, in the event Form S-3 is unavailable to the Company,
Form S-1 or other then-available form (the “Registration Statement”), in each case as promptly as practicable, providing for the resale of all of the then-outstanding Registrable Securities in
compliance with SEC Rule 415, including the prospectus forming part of the Registration Statement. The Registration Statement shall cover the resale on a continuous basis pursuant to SEC Rule 415 of all Registrable Securities. The Investor and its
counsel shall have a reasonable opportunity to review and comment upon the Registration Statement or any amendment thereto and any related prospectus prior to its filing with the SEC. The Registration Statement (including any amendments or
supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Registration Statement shall register only the Registrable Securities and no other securities of the Company. 

(b)    Notwithstanding the foregoing obligations, the Company may, upon written notice to the Investor,
for a reasonable period of time, not to exceed 45 days in the case of clauses (A) and (B) below, or 30 days in the case of clause (C) below (each, a “Blackout Period”), delay the filing of the Registration
Statement or a request for acceleration of the effective date, or suspend the effectiveness of the Registration Statement, in the event that (A) the Company is engaged in any activity or transaction or preparations or negotiations for any
activity or transaction that the Company desires to keep confidential for business reasons, if the Company determines in good faith that the public disclosure requirements imposed on the Company under the Securities Act in connection with the
Registration Statement would require at that time disclosure of such activity, transaction, preparations or negotiations and such disclosure could result in material harm to the Company or its business transactions or activities, (B) the
Company does not yet have appropriate financial statements of any acquired or to be acquired entities necessary for filing, or (C) any other event occurs that makes any statement of a material fact made in the Registration Statement, including
any document incorporated by reference therein, untrue or that requires the making of any additions or changes in the Registration Statement in order to make the statements therein not misleading; provided,
however, that in the case of a Blackout Period pursuant to clause (A) above, the Blackout Period shall terminate upon the earlier of such 45-day period or the
completion, resolution or public announcement of the relevant transaction or event. If the Company suspends the effectiveness of the Registration Statement pursuant to this section, the Company shall, as promptly as reasonably practicable following
the termination of the circumstance which entitled the Company to do so, take such actions as may be necessary to reinstate the effectiveness of the Registration Statement and give written notice to the Investor authorizing the Investor to resume
offerings and sales pursuant to the Registration Statement. If as a result thereof the prospectus included in the Registration Statement has been amended or supplemented to comply with the requirements of the Securities Act, the Company shall
enclose such revised prospectus with the notice to Investor given pursuant to this section. The Company shall be entitled to exercise its rights under this Section 4.1(b) not more than once in any six (6) month period;
provided, however, that the aggregate number of days of all Blackout Periods hereunder shall not exceed seventy-five (75) days in any twelve (12) month period. After the expiration of any Blackout Period and without
further request from the Investor, the Company shall effect the filing (or if required amendment or supplement) of the Registration Statement, or the filing of other documents, as necessary to allow the Investor to resell the Registrable
Securities as set forth herein. 

  
 7 

 4.2    Obligations of the Company. The Company shall:

 (a)    use its commercially reasonable efforts to ensure that registration on Form S-3 remains available to the Company for any period during which the Investor or the Investor’s Affiliates holds any Registrable Securities; 

(b)    use its commercially reasonable efforts to cause the Registration Statement to become effective
under the Securities Act within ninety (90) days after it is filed with the SEC; 
 (c)    use its
commercially reasonable efforts to keep the Registration Statement continuously effective until the earlier of (i) two (2) years following the first day of effectiveness of the Registration Statement (subject to extension pursuant to
Section 4.3(b) or Section 4.3(c)) and (ii) such time that all Registrable Securities covered by the Registration Statement are no longer Registrable Securities (the “Registration Period”); 

(d)    furnish to the Investor such number of copies of a prospectus, including a preliminary prospectus,
as required by the Securities Act, and such other documents as the Investor may reasonably request in order to facilitate the disposition of Registrable Securities; 

(e)    promptly following its actual knowledge thereof, notify the Investor: 

(i)    of the time when the Registration Statement has been declared effective or when a
supplement or amendment to any prospectus forming a part of such Registration Statement has been filed (other than any deemed amendment of the Registration Statement by means of a document filed by the Company under the Exchange Act); 

(ii)    after the Registration Statement becomes effective, of any request by the SEC
that the Company amend or supplement the Registration Statement or prospectus forming a part of the Registration Statement or for additional information; and 

(iii)    of the issuance by the SEC or any other Governmental Entity of any stop order
suspending the effectiveness of the Registration Statement or the initiation of any Proceeding for such purpose; provided that the Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other
suspension of effectiveness of the Registration Statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order or
suspension at the earliest practical time. 

  
 8 

 (f)    use its commercially reasonable efforts to
(i) register and qualify the Registrable Securities covered by the Registration Statement under the securities or “blue sky” laws of such jurisdictions within the United States as shall be reasonably requested by the Investor;
(ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration
Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify
the Registrable Securities for sale in such jurisdictions; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or otherwise become subject to taxation or service
of process in suits in any such jurisdictions where it is not already so qualified or subject. The Company shall promptly notify the Investor of the receipt by the Company of any notification with respect to the suspension of the registration or
qualification of any of the Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threat of any Proceeding for such purpose.

 (g)    in the event of any underwritten public offering of Registrable Securities, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 

(h)    (i) use its commercially reasonable efforts to cause all the Registrable Securities covered by the
Registration Statement to be listed on each national securities exchange or trading system on which the Common Stock is then listed and (ii) pay all associated fees and expenses with such listing; 

(i)    provide a transfer agent and registrar for all Registrable Securities and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of the Registration Statement; 

(j)    promptly make available for inspection by the Investor or its representatives and agents, any
managing underwriter(s) participating in any underwritten offering pursuant to the Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the Investor, all financial and other records,
pertinent corporate documents and properties of the Company during normal business hours at the offices where such information is typically kept, and cause the Company’s officers, directors, employees and independent accountants to supply all
information reasonably requested by the Investor or any such underwriter, attorney, accountant, agent or other representative, in each case, as reasonably necessary or advisable to verify the accuracy of the information in the Registration Statement
and to conduct appropriate due diligence in connection therewith as is customary for similar due diligence examinations, provided that, any information that is designated in writing by the Company, in good faith, as confidential at the
time of delivery of such information shall be kept confidential by the Investor or any such underwriter, attorney, accountant, agent or other representative; 

(k)    promptly (i) incorporate in a prospectus supplement or post-effective amendment to the
Registration Statement such information as the Investor reasonably believes is required by the Securities Act to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with
respect to the number of Registrable Securities being sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities; and (ii) make all required filings of such prospectus supplement or
post-effective amendment promptly after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment; 

  
 9 

 (l)    use its commercially reasonable efforts to cause the
Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental agencies or authorities in the United States as may be necessary to consummate the disposition of such Registrable Securities;
and 
 (m)    take all other reasonable actions as necessary and reasonably requested by the Investor
to expedite and facilitate disposition by the Investor of Registrable Securities pursuant to the Registration Statement. 

4.3    Obligations of the Investor. The Investor shall: 

(a)    furnish to the Company such information regarding the Investor and its plan and method of
distribution of such Registrable Securities as the Company may, on advice of counsel, reasonably determine is required by applicable law, including, without limitation, information required by Item 507 of
Regulation S-K promulgated under the Securities Act. The Company shall notify the Investor in writing of any such information that the Company reasonably requires from the Investor, and the Investor shall
furnish such required information to the Company as promptly as practical after being notified by the Company, provided that, any information that is designated in writing by the Investor, in good faith, as confidential at the time of
delivery of such information shall be kept confidential by the Company and shall not be disclosed except to the Company’s counsel, for purposes of determining whether applicable law requires such information to be disclosed in the Registration
Statement; 
 (b)    upon receipt of any notice from the Company of the occurrence of any event of the
type described in Sections 4.2(e)(ii) or 4.2(e)(iii), discontinue disposition of Registrable Securities covered by the Registration Statement and suspend use of the Registration Statement or prospectus forming a part of the Registration
Statement until the Company has provided an amendment or supplement to the Registration Statement or prospectus or the Company has advised that the use of the Registration Statement or prospectus may be resumed, provided that, in the event
that the Company gives any such notice, the period of time for which the Registration Statement must remain effective as set forth in Section 4.2(c) will be extended by the number of days during the time period from and including the date of
the giving of such notice to and including the date when the Company has either provided an amendment to the Registration Statement or prospectus or advised that the use of the Registration Statement or prospectus may be resumed; 

(c)    upon receipt of any notice from the Company of a Blackout Period, the Investor will discontinue
disposition of Registrable Securities covered by the Registration Statement and suspend use of the Registration Statement or prospectus forming a part of the Registration Statement until the Company has provided an amendment or supplement to the
Registration Statement or prospectus or the Company has advised that the use of the Registration Statement or prospectus may be resumed, provided that, in the event that the Company gives any such notice, the period of time for which
the Registration Statement must remain effective as set forth in Section 4.2(c) will be extended by the number of days during the time period from and including the date of the giving of such notice to and including the date when the Company
has either provided an amendment to the Registration Statement or prospectus or advised that the use of the Registration Statement or prospectus may be resumed; and 

  
 10 

 (d)    in the event of any underwritten public offering of
Registrable Securities, the Investor shall enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering. 

4.4    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection
with registrations, filings, or qualifications pursuant to this Section 4, including, without limitation, all registration, filing, listing and qualification fees, printers’ and accounting fees, and fees and disbursements of counsel for
the Company, shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration process begun pursuant to Section 4.1 if the registration request is
subsequently withdrawn at the request of the Investor; provided further that if, at the time of such withdrawal, the Investor shall have learned of any fact or circumstance that has arisen since the time of the Investor’s request
or was not known to the Investor at the time of the Investor’s request, and in each case is reasonably likely to have a material adverse effect on the financial condition or business of the Company and its subsidiaries considered as one
enterprise, and has withdrawn the request with reasonable promptness after learning of such information, then the Company shall be required to pay all of such expenses. All Selling Expenses relating to Registrable Securities registered pursuant to
this Section 4 shall be borne and paid by the Investor. 
 4.5    Indemnification. If any
Registrable Securities are included in the Registration Statement under this Section 4: 

(a)    To the extent permitted by law, the Company will indemnify and hold harmless the Investor and its
officers, directors, employees, agents, managers, partners and shareholders, and each Person who controls such member (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), from and against any Damages,
and the Company will reimburse the Investor, controlling Person or other aforementioned Person for any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or Proceeding from which Damages may
result; provided, however, that the indemnity agreement contained in this Section 4.5(a) shall not apply to amounts paid in settlement of any such claim or Proceeding if such settlement is effected without the consent of the Company,
which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished
by or on behalf of the Investor, controlling Person or other aforementioned Person expressly for use in connection with the Registration Statement. 

  
 11 

 (b)    To the extent permitted by law, the Investor will
indemnify and hold harmless the Company, its directors, its officers who have signed the Registration Statement and each Person who controls the Company (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act) against any Damages, and the Investor will reimburse the Company, controlling Person or other aforementioned Person for any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or
Proceeding from which Damages may result, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of the
Investor expressly for use in connection with the Registration Statement; provided, however, that the indemnity agreement contained in this Section 4.5(b) shall not apply to amounts paid in settlement of any such claim or
Proceeding if such settlement is effected without the consent of the Investor, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by the Investor by way of
indemnity or contribution under Section 4.5(b) exceed the proceeds from the offering received by the Investor (net of any underwriting discounts and commissions paid by the Investor), except in the case of fraud or willful misconduct by the
Investor. 
 (c)    Promptly after receipt by an indemnified party under this Section 4.5 of
notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 4.5, give the indemnifying party notice of the commencement thereof. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party,
the indemnifying party shall be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the
aforesaid notice from such indemnified party, to assume the defense thereof with counsel selected by the indemnifying party that is reasonably satisfactory to such indemnified party; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. Upon receipt of
notice from the indemnifying party to such indemnified party of such indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such
indemnified party under this Section 4.5 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless the indemnified party shall have employed separate counsel in accordance with
the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate firm of attorneys (together with local counsel), representing all of the indemnified parties
who are parties to such action). The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 4.5, except to the extent that the
indemnifying party would be materially prejudiced as a proximate result of such failure to notify. Without the prior written consent of the indemnified party, no indemnifying party may effect any settlement of any pending or threatened action unless
such settlement includes an unconditional release of such indemnified party from all liability arising out of such proceeding. 

  
 12 

 4.6    Reports Under Exchange Act by the Company. With
a view to making available to the Investor the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3 or Form S-1, the Company shall: 

(a)    make and keep available adequate current public information, as those terms are understood and
defined in SEC Rule 144; 
 (b)    use commercially reasonable efforts to file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; 

(c)    furnish upon request to the Investor (i) to the extent accurate, a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144, the Securities Act, and the Exchange Act, or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3; (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents filed by the Company with the SEC; and (iii) such other information as may be
reasonably requested in availing the Investor of any rule or regulation of the SEC that permits the selling of any such securities without registration; and 

(d)    take such additional action as is requested by the Investor to enable the Investor to sell the
Registrable Securities pursuant to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company’s transfer agent as may be reasonably requested from time to
time by the Investor and otherwise fully cooperate with the Investor and the Investor’s broker to effect such sale of securities pursuant to Rule 144. 

4.7    Restrictive Legends. Upon the request of the Investor or an Investor Affiliate, in
connection with any sale of Registrable Securities pursuant to the Registration Statement or pursuant to SEC Rule 144, the Company will cooperate with the Investor or such Investor Affiliate to facilitate the timely preparation and delivery of the
Registrable Securities to be delivered to a transferee free of all restrictive legends. The Company will additionally cooperate with the Investor or an Investor Affiliate in connection with any financing arrangement permitted under Section 7
that the Investor or such Investor Affiliate plans to enter into to allow for the pledge of Registrable Securities as collateral for such financing arrangements (including perfection of such pledges). 

5.      Lock-up Agreements. If requested by the
managing underwriter or underwriters in an underwritten offering of Common Stock or other securities by the Company, and provided that all executive officers and directors of the Company are bound by similar agreements, the Investor will, and
will cause each Investor Affiliate to, not effect any public sale or distribution of Common Stock (except as part of such underwritten offering, if applicable), including a sale pursuant to SEC Rule 144 or any swap or other economic arrangement that
transfers to another Person any of the economic consequences of owning Common Stock, during the period commencing on the date of the request (which will be no earlier than 14 days prior to the expected “pricing” of such offering) and
continuing for not more than 90 days after the date of the prospectus relating to such offering (or final prospectus supplement if such offering is made pursuant to a shelf registration statement), pursuant to which such offering will be made. In
the event that a managing underwriter or underwriters requests that the Investor and any Investor Affiliate not make public sales or distributions pursuant to this Section 5, the Investor will, and will cause each Investor Affiliate to, enter
into a written agreement memorializing such obligations, which agreement will otherwise be on customary terms, provided that all executive officers and directors of the Company have entered into similar agreements. 

  
 13 

 6.    Reports Under Exchange Act by the Investor and
Investor Affiliates. The Investor acknowledges and agrees that the Investor and each Investor Affiliate will be solely responsible for any required filings under Sections 13 and 16 of the Exchange Act in connection with any acquisition or
disposition of Common Stock. The Investor will provide the Company with a copy of any such filing contemporaneously with such filing being submitted to the SEC. 

7.    Resale Limitations. The Investor hereby agrees, and will cause each Investor Affiliate, not
to, directly or indirectly, in one or more transactions, sell, assign, transfer or otherwise encumber, whether by pledge or otherwise (other than pledges of Common Stock pursuant to a credit agreement or other financing arrangement), through swap or
hedging transactions or otherwise (each, a “Transfer”), without the written consent of the Company, (i) any Common Stock during the period commencing on the date hereof and ending on the
six-month anniversary of the date hereof, (ii) 50.0% or more, in the aggregate, of the number of shares of Common Stock held by the Investor on the date hereof during the period commencing on the six-month anniversary of the date hereof and ending on the first anniversary of the date hereof, (iii) any Warrant Shares during the period commencing on the date hereof and ending on the Termination Date,
(iv) to any Person or group of Persons who owns or, after giving effect to such Transfer, would own greater than 10.0% of the then-outstanding Common Stock of the Company or (v) to any Person who is a competitor of the Company as
reasonably determined by the Company Board; provided, however, that, subject to compliance with Section 10(a), the Investor and the Investor Affiliates may effect transfers of Common Stock amongst themselves without restriction.
The Investor hereby agrees, and will cause each Investor Affiliate, not to, directly or indirectly, in one or more transactions, loan any Common Stock. Notwithstanding anything to the contrary in the foregoing, this Section 7 will not prohibit
the sale of any Common Stock in connection with a Change of Control. 
 8.    Company Board. 

8.1    Subject to Section 8.4, so long as (a) the Collaboration Agreement has been entered into
and remains in effect and (b) the Investor and the Investor Affiliates collectively beneficially own 15.0% or more of the outstanding Common Stock, the Investor shall have the right to nominate two Investor Directors pursuant to this
Section 8, at every annual meeting of the stockholders of the Company in which directors are generally elected, including, without limitation, at every adjournment or postponement thereof. 

8.2    Subject to Section 8.4, so long as (a) the Collaboration Agreement has been entered into
and remains in effect and (b) the Investor and the Investor Affiliates collectively beneficially own less than 15.0% of the outstanding Common Stock and 5.0% or more of the outstanding Common Stock, the Investor shall have the right to nominate
one Investor Director pursuant to this Section 8, at every annual meeting of the stockholders of the Company in which directors are generally elected, including, without limitation, at every adjournment or postponement thereof. With respect to
the Company’s 2018 annual meeting of stockholders (the “2018 Annual Meeting”), the Company Board shall, to the extent necessary, increase the size of the Company Board, and nominate one Investor Director for election at the
2018 Annual Meeting, which Investor Director initially will be Dr. Tadahisa Kagimoto; provided, however, that if Company has filed its proxy statement for the 2018 Annual Meeting prior to the date that the Collaboration Agreement
has been entered into, the Company will not be obligated to nominate the Investor Director at the 2018 Annual Meeting, but instead will, to the extent necessary, increase the size of the Company Board, and appoint one Investor Director,
Dr. Tadahisa Kagimoto, to the Company Board promptly after the 2018 Annual Meeting. 

  
 14 

 8.3    The following procedures shall be followed with
respect to the nomination of Investor Directors pursuant to Section 8.1 or Section 8.2: 

(a)    For purposes of whether the Investor has a right to nominate an Investor Director pursuant to
Section 8.1 or Section 8.2, the Investor and the Investor Affiliates’ beneficial ownership of the outstanding Common Stock will be measured as of the January 31st immediately preceding such annual meeting. 

(b)    No later than February 10th of each year, the Investor shall provide the Company Board with
the Investor’s nominee(s) for the Investor Director(s), along with any other information reasonably requested by the Company Board. With respect to the Investor nominee(s), the Investor shall use its best efforts to ensure that any such nominee
satisfies any criteria and guidelines for director nominees that may be in effect from time to time, as well qualifies as “independent” under the rules of the NASDAQ Stock Market LLC (or the principal other U.S. national or regional
securities exchange on which the Common Stock (or such other security) is then listed) and the Exchange Act, including the rules and regulations promulgated by the SEC thereunder (the “Independence Requirements”), other than an
inability to qualify as “independent” solely as a result of such nominee’s relationship with the Investor or any Investor Affiliate. The Company shall be entitled to rely on any written direction from the Investor regarding the
Investor’s nominee(s) on behalf of the Investor without further action by the Company. 

(c)    Within 20 days of receiving the Investor’s nominee(s) for the Investor Director(s) in
accordance with Section 8.3(b), the Company Board or any authorized committee thereof shall have made a good faith and reasonable determination as to the suitability of the Investor’s nominee(s) for Investor Director(s) and shall notify
the Investor of its determination in writing. Notwithstanding the foregoing, Dr. Tadahisa Kagimoto is deemed to be an acceptable nominee. 

(d)    If the Company Board or any authorized committee thereof approves of the Investor’s
nominee(s) for Investor Director(s), the Company Board shall recommend that the stockholders vote to elect such Investor’s nominee(s) at the next annual meeting of stockholders at which directors will be generally elected. 

(e)    If the Company Board or any authorized committee thereof raises a reasonable objection to one or
both of the Investor’s nominees, as the case may be, for the Investor Director(s), then the Investor and the Company Board shall use commercially reasonable efforts to agree on the nominee(s) for such Investor Director(s), and if the Investor
and the Company Board cannot agree on the nominee(s) on or before the twentieth day prior to the proposed filing of the Company’s annual proxy statement, then such nominee for Investor Director(s) shall not be nominated by the Company at such
annual meeting. 

  
 15 

 (f)    If one or both of the Investor nominees is not
nominated (as described in the foregoing clause (e)), then as soon as practicable after the annual meeting, the Investor and the Company Board shall use commercially reasonable efforts to agree on the nominee(s) for such Investor Director(s), which
nominee(s) shall be appointed as director(s) by the Company Board promptly after such agreement is reached. 

8.4    Notwithstanding anything to the contrary in this Agreement and without any further action by the
Company, the Investor’s right to nominate any Person to the Company Board shall automatically terminate, and be of no further force and effect, on the date that the Investor and the Investor Affiliates collectively beneficially own less than
5.0% of the outstanding Common Stock, other than solely as a result of issuances of additional shares of Common Stock by the Company during the 90-day period ending on January 31st of any given year. The
Investor shall promptly, but in any case within five (5) days, provide notice to the Company upon Investor and the Investor Affiliates collectively ceasing to beneficially own 5.0% or more of the outstanding Common Stock as a result of Investor
sales of Common Stock. 
 8.5    During the Standstill Period, so long as the Investor has a right to
nominate an Investor Director pursuant to Section 8.1 or Section 8.2, the Company will use reasonable best efforts to ensure that the size of the Company Board is not increased beyond eight members (excluding any Investor Directors)
without the written consent of the Investor. 
 8.6    Any Investor Director, upon appointment or
election to the Company Board, will be governed by the same protections and obligations as all other directors of the Company, including, without limitation, protections and obligations regarding customary liability insurance for directors and
officers, confidentiality, conflicts of interests, fiduciary duties, trading and disclosure policies, director evaluation process, director code of ethics, director share ownership guidelines, stock trading and
pre-approval policies, and other governance matters. 

9.    Right of Consultation and Participation. During the Standstill Period, so long as the
Collaboration Agreement has been entered into and remains in effect: 
 9.1    Prior to the Company
(a) undertaking an underwritten public offering of Common Stock and/or Common Stock Equivalents (an “Underwritten Offering”), (b) undertaking a private offering exempt from the registration requirements of the Securities Act of
Common Stock and/or Common Stock Equivalents for cash other than (i) pursuant to its existing equity facility or any replacement equity facility (which is covered in clause (c)) or (ii) pursuant to compensation arrangements for its
employees, directors or consultants (a “Private Placement”) or (c) issuing Common Stock pursuant to its existing equity facility or any replacement equity facility (an “Equity Draw”), the Company will provide
prior notice to, and consult with, the Investor regarding such Underwritten Offering, Private Placement or Equity Draw, as applicable. 

  
 16 

 9.2    If the Company proceeds with any Underwritten
Offering, the Investor may participate in such Underwritten Offering by placing an order to purchase and, if such order is filled by the underwriters, purchase an amount of Common Stock and/or Common Stock Equivalents so that the Investor, together
with the Investor Affiliates, is able to maintain at least up to the same percentage beneficial ownership of the outstanding Common Stock immediately prior to giving effect to the Underwritten Offering, up to 19.9% of the Common Stock and/or Common
Stock Equivalents being offered (such amount of the Common Stock and/or Common Stock Equivalents, the “Underwritten Pro Rata Share”). If the Company proceeds with any Private Placement, the Investor will be entitled to participate
in such Private Placement and purchase an amount of Common Stock and/or Common Stock Equivalents so that the Investor, together with the Investor Affiliates, is able to maintain at least up to the same percentage beneficial ownership of the
outstanding Common Stock immediately prior to giving effect to the Private Placement, up to 19.9% of the Common Stock and/or Common Stock Equivalents being offered (such amount of the Common Stock and/or Common Stock Equivalents, the
“Private Placement Pro Rata Share”). If the Company Proceeds with any Equity Draw, it shall provide written notice to the Investor of number of shares of Common Stock sold and the sale price of such shares promptly after the
completion of such Equity Draw, and the Investor may provide notice to the Company, within ten (10) days of its receipt from such notice from the Company, of its intent to purchase up to an amount of Common Stock so that the Investor, together
with the Investor Affiliates, is able to maintain at least up to the same percentage beneficial ownership of the outstanding Common Stock immediately prior to giving effect to the Equity Draw, up to 19.9% of the Common Stock sold in the Equity Draw
(such amount of the Common Stock, the “Equity Draw Pro Rata Share”) from the Company in a private offering exempt from the registration requirements of the Securities Act (a “Private Placement Notice”). If the
Investor provides a Private Placement Notice to the Company, the Investor and the Company agree that they will negotiate in good faith to enter into a binding securities purchase agreement within 30 days of the delivery of such Private Placement
Notice pursuant to which the Company will agree to sell to the Investor Common Stock in an amount equal to the Equity Draw Pro Rata Share at a price per share to be agreed upon by the Company and Investor and substantially similar to the price per
share in the Equity Draw so long as such sale would not require the approval of the Company’s stockholders under the rules of the NASDAQ Stock Market LLC (or the principal other U.S. national or regional securities exchange on which the Common
Stock is then listed). To the extent that the purchase of any of the Underwritten Pro Rata Share, Private Placement Pro Rata Share or Equity Draw Pro Rata Share by the Investor or any Investor Affiliate would require the approval of the
Company’s stockholders under the rules of the NASDAQ Stock Market LLC (or the principal other U.S. national or regional securities exchange on which the Common Stock is then listed), then such Pro Rata Share shall be reduced to an amount that
would not require such stockholder approval. Notwithstanding anything to the contrary in the foregoing, neither the Investor nor any Investor Affiliate shall be permitted to acquire any shares of Common Stock and/or Common Stock Equivalents pursuant
to this Section 9 to the extent that after giving effect to such acquisition, the Investor (together with the Investor Affiliates, and any other Persons acting as a group together with the Investor or any of the Investor Affiliates), would
beneficially own shares of Common Stock in excess of the Beneficial Ownership Limitation. 

  
 17 

 9.3    If the Investor reasonably believes that, giving
effect to an exercise of the Warrant in full (for the avoidance of doubt, disregarding any portion of the Warrant that has expired as of such date), the Investor, together with the Investor Affiliates, will not beneficially own 19.9% of the Common
Stock, the Company agrees to negotiate in good faith with the Investor regarding, at the Investor’s option, a potential sale of additional warrants exercisable for shares of Common Stock to the Investor or a potential sale of additional shares
of Common Stock to the Investor. 
 10.    Miscellaneous. 

(a)    Successors and Assigns. Any assignment of this Agreement or any of the rights or
obligations under this Agreement (whether by operation of law or otherwise) by either the Company, on the one hand, or the Investor, on the other hand, will be void, invalid and of no effect without the prior written consent of the Investor (in the
case of the Company) or the Company (in the case of the Investor); provided, however, that the rights under this Agreement may be assigned (but only with all related obligations) by the Investor to one or more Investor Affiliates so
long as the assignee(s) agree in writing to be bound by the terms and conditions of this Agreement; provided, further, that any such assignment will not release, or be construed to release, the Investor from its duties and obligations
under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

(b)    Termination. This Agreement will automatically terminate with respect to the Investor at
such time as the Investor, together with the Investor Affiliates, or any assignee of the Investor pursuant to Section 10(a) of this Agreement, together with such assignee’s Affiliates, no longer beneficially owns at least 3.0% of the
Common Stock. Upon such termination, neither the Company nor the Investor will have any further obligations or liabilities to each other hereunder; provided that such termination will not relieve any party from liability for any breach
of this Agreement prior to such termination. 
 (c)    Governing Law. This Agreement and any
controversy arising out of or relating to this Agreement will be governed by and construed in accordance with the laws of the State of New York as to matters within the scope thereof, and as to all other matters will be governed by and construed in
accordance with the internal laws of New York, without regard to conflict of laws principles that would result in the application of any law other than the law of the State of New York. 

(d)    Jurisdiction; Venue. Each of the Company and the Investor hereby submits and consents
irrevocably to the exclusive jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York for the interpretation and enforcement of the provisions of this Agreement. Each of the
Company and the Investor also agrees that the jurisdiction over the person of such parties and the subject matter of such dispute shall be effected by the mailing of process or other papers in connection with any such action in the manner provided
for in Section 10(h) or in such other manner as may be lawful, and that service in such manner shall constitute valid and sufficient service of process. 

  
 18 

 (e)    Jury Trial. EACH OF THE COMPANY AND THE
INVESTOR HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 (f)    Counterparts. This Agreement may be executed in two or more counterparts, each of
which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may also be executed and delivered by portable document format (pdf) and in two or more counterparts, each of which will be
deemed an original, but all of which together will constitute one and the same instrument. 

(g)    Interpretation. The titles and subtitles used in this Agreement are for convenience only
and are not to be considered in construing or interpreting this Agreement. The use of the words “include” or “including” in this Agreement will be deemed to be followed by the words “without limitation.” The use of the
words “or,” “either” or “any” will not be exclusive. References to statutes will include all regulations promulgated thereunder, and references to statutes will be construed to include all statutory and regulatory
provisions consolidating, amending or replacing the statute or regulation as of the date hereof. The parties have participated jointly in the negotiation and drafting of this Agreement. 

(h)    Notices. All notices, requests, demands, and other communications hereunder will be in
writing (which will include communications by e-mail) and will be delivered (i) in person or by courier or overnight service or (ii) by e-mail with a copy
delivered as provided in clause (i), as follows: 
 If to the Company: 

Athersys, Inc. 

3201 Carnegie Avenue 

Cleveland, Ohio 44115 

Attention: Laura Campbell 

Telephone: (216) 431-9900 

E-mail: lcampbell@athersys.com 

with a copy (which will not constitute notice) to: 

Jones Day 

North Point 

901 Lakeside Avenue 

Cleveland, Ohio 44114 

Attention: Michael J. Solecki 

Telephone: (216) 586-7103 

E-mail: mjsolecki@jonesday.com 

  
 19 

 If to the Investor: 

HEALIOS K.K. 

Attention: General Manager of Finance and Accounting Division 

World Trade Center Bldg. 15F 

2-4-1 Hamamatsucho, 

Minato-ku, Tokyo, 135-6115 Japan 

Facsimile: +81-3-3434-7231 

with a copy (which will not constitute notice) to: 

Morrison & Foerster LLP 

Shin-Marunouchi Building, 29th Floor 

1-5-1 Marunouchi, Chiyoda-ku,
Tokyo 
 100-6529, Japan 

Telephone: +81-3-3214-6522 

Facsimile: +81-3-3214-6512 

Email: RLaxer@mofo.com 

Attention: Randy S. Laxer 

and to: 

Morrison & Foerster LLP 

250 West 55th Street 

New York, NY 10019-9601, U.S.A. 

Telephone: +1 (212) 468-8000 

Facsimile: +1 (212) 468-7900 

Email: JBell@mofo.com 

Attention: Jeffrey Bell 

All such notices and other communications shall be deemed to have been given and received (1) in the case of personal
delivery, on the date of such delivery, (2) in the case of delivery by email or facsimile, (A) when delivered prior to 5:00 p.m. (New York time) on a Business Day or (B) if delivered after 5:00 p.m. on a Business Day or on a day that
is not a Business Day, on the first Business Day following the date of delivery, (3) in the case of delivery by nationally recognized overnight courier, on the second Business Day following the date when sent, and (4) in the case of
mailing, on the fifth Business Day following such mailing. 
 (i)    Amendments and Waivers. Any
term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of each party. No waivers of
or exceptions to any term, condition or provision of this Agreement, in any one or more instances, will be deemed to be or construed as a further or continuing waiver of any such term, condition or provision. 

(j)    Severability. In case any one or more of the provisions contained in this Agreement is for
any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision of this Agreement, and such invalid, illegal or unenforceable provision will be reformed and
construed so that it will be valid, legal and enforceable to the maximum extent permitted by law. 

  
 20 

 (k)    Entire Agreement. This Agreement constitutes
the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly superseded hereby.

 [Signatures follow.] 

  
 21 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above. 
  

			
	 ATHERSYS, INC.

	
	 By:  /s/ Gil Van Bokkelen

	 Name:
	 	 Gil Van Bokkelen

	 Title:
	 	 Chairman & CEO

	
	 HEALIOS K.K.

	
	 By: /s/ Hardy TS Kagimoto

	 Name:
	 	 Hardy TS Kagimoto

	 Title:
	 	 President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]